capecitabine has been researched along with Breast Neoplasms in 1099 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (0.91) | 18.2507 |
| 2000's | 382 (34.76) | 29.6817 |
| 2010's | 555 (50.50) | 24.3611 |
| 2020's | 152 (13.83) | 2.80 |
| Authors | Studies |
|---|---|
| Amoroso, D; Baldelli, A; Berardi, R; Butera, A; Cagossi, K; Capici, S; Cavanna, L; Cazzaniga, ME; Ciccarese, M; Cinieri, S; Clivio, L; Cogliati, V; Cretella, E; De Conciliis, E; Di Mauro, P; Febbraro, A; Ferraù, F; Ferzi, A; Fontana, A; Gambaro, AR; Garrone, O; Gebbia, V; Generali, D; Gianni, L; Giovanardi, F; Grassadonia, A; Leonardi, V; Marchetti, P; Montagna, E; Musolino, A; Nicolini, M; Putzu, C; Riccardi, F; Santini, D; Saracchini, S; Sarobba, MG; Sarti, S; Schintu, MG; Scognamiglio, G; Spadaro, P; Taverniti, C; Toniolo, D; Torri, V; Tralongo, P; Turletti, A; Valenza, R; Valerio, MR; Vallini, I; Vici, P | 1 |
| Artacho Criado, S; Díaz-Acedo, R; Galván Banqueri, M; Gutiérrez Pizarraya, A; Jiménez Galán, R; Marcos Rodríguez, JA; Márquez Saavedra, E; Rodríguez-de-la-Borbolla-Artacho, M | 1 |
| Cherem-Kibrit, M; Colmenero-Mercado, JO; Deneken-Hernandez, Z; Gutiérrez-Andrade, L; Rodríguez-Gutiérrez, G | 1 |
| Babu, S; Bajaj, V; Bhat, G; Biswas, G; Bondarde, SA; Boya, RR; Choudhury, K; Gupta, S; Joshi, N; Khan, MA; Lakshmaiah, KC; Maksud, TM; Mamillapalli, G; Neve, RS; Patel, AA; Patel, JG; Patel, P; Patil, P; Raja, G | 1 |
| Dizdar, O; Guven, DC; Taban, H | 1 |
| Cao, Y; Chen, L; Gou, P; Hu, X; Lin, Z; Yao, G; Ye, C; Zeng, X; Zhou, W | 1 |
| Berliere, M; Canon, JL; Dufour, V; Duhoux, FP; Migeotte, A; Taylor, D; van Maanen, A | 1 |
| Burns, K; Findlay, M; Helsby, N; Porter, D; Strother, M | 1 |
| Abu-Shahin, FI; Brown, EN; Liu, L | 1 |
| Battista, MJ; Hasenburg, A; Krajnak, S; Schmidt, M | 1 |
| Andrejic Visnjic, B; Kolarov Bjelobrk, I; Pesic, J; Petrovic, N; Radic, J; Trifunovic, J; Vidovic, V; Vranjkovic, B | 1 |
| Borges, V; Cameron, D; Carey, LA; Curigliano, G; Feng, W; Gelmon, K; Hamilton, E; Hortobagyi, GN; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Murthy, R; Okines, A; Paplomata, E; Pegram, M; Ramos, J; Slamon, D; Winer, E | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Kojima, Y; Nishikawa, T; Noguchi, E; Okuya, T; Satomi-Tsushita, N; Shimoi, T; Sudo, K; Sumiyoshi-Okuma, H; Takamizawa, S; Tanioka, M; Yazaki, S; Yonemori, K | 1 |
| Chen, X; Chen, Z; Dong, F; Franceschini, G; Gao, Z; Hao, C; Ishii, N; Li, L; Li, X; Liu, L; Liu, Z; Lv, H; Niu, L; Orlandi, A; Ouyang, Q; Qiao, J; Ricci, F; Song, Y; Sun, T; Takabe, K; Verschraegen, C; Xiao, H; Yan, M; Yang, J; Yang, X; Zhang, G; Zhang, M | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Fang, H; Liu, M; Qian, S | 1 |
| Henry, NL; Hertz, DL; Koo, K; Pasternak, AL; Sahai, V | 1 |
| Huang, X; Ni, J; Xi, X; Yang, F; Yuan, H | 1 |
| Bachelot, T; Carton, M; Cheaib, B; Chevrot, M; Cottu, PH; Courtinard, C; Dalenc, F; Debled, M; Desmoulins, I; Diéras, V; Emile, G; Eymard, JC; Ferrero, JM; Goncalves, A; Jacot, W; Leheurteur, M; Moinard-Butot, F; Mouret-Reynier, MA; Patsouris, A; Petit, T; Pflumio, C; Saint-Martin, C; Uwer, L; Vanlemmens, L | 1 |
| Barrios, CH; Bear, HD; Joensuu, H; Loibl, S; Martin, M; Miralles, JJ; Möbus, V; Muss, H; Nekljudova, V; Nitz, U; O'Shaughnessy, J; Reimer, T; Seither, F; Steger, GG; Toi, M; Untch, M; van Mackelenbergh, MT | 1 |
| Elyasi, S; Hosseini, S; Rasta, S; Taghizadeh-Kermani, A | 1 |
| Chang, H; Chen, R; Cheng, J; Hu, T; Peng, X; Wang, J; Wang, Q; Xie, Y | 1 |
| Jacot, W; Quesada, S | 1 |
| Ennett, MD; Kaplan, HG; Kullnat, JA; Rinn, KJ; Scott, EL; Wu, AY; Yan, F | 1 |
| Alba, E; Alonso-Romero, JL; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, MI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodríguez, J; Gil-Gil, M; Huang, X; Kahan, Z; Margelí, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Sánchez-Rovira, P; Santaballa, A; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Chen, C; Ran, J; Yang, Q | 1 |
| Ikemura, K; Okuda, M; Shimazu, K; Shintani, T; Takemura, M; Toyozumi, Y; Ueda, M; Yoshinami, T | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| Arıkan, R; Atcı, MM; Ay, S; Ayhan, M; Bayram, E; Dülgar, Ö; Gümüş, M; Öven, BB; Özcan, E; Ozyukseler, DT; Selvi, O; Yasin, Aİ | 1 |
| Alder, L; Anders, CK; Sammons, S; Van Swearingen, AED | 1 |
| Altundag, K | 6 |
| Pizano, PE; Suárez, EU | 1 |
| Barrios, CH; de Resende, CAA; Gonçalves, AC; Reinert, T | 1 |
| Choi, SH; Choi, SJ; Jang, JK; Jung, KH; Kang, HJ; Kim, DW; Lee, JB; Lee, SS; Park, HJ | 1 |
| Allen, M; Cunningham, N; Johnston, S; Kipps, E; Lee, KA; McGrath, S; Mohammed, K; Noble, J; Okines, AFC; Parton, M; Ring, A; Shepherd, S; Turner, NC | 1 |
| Clark, O; Davis, C; Durbin, L; Hawthorne, S; Kanas, G; Li, S; Murali, B; Vijaykumar, S; Yang, L; Zhao, L | 1 |
| Boscolo Bielo, L; Burstein, HJ; Curigliano, G; Ferraro, E; Giugliano, F; Trapani, D | 1 |
| Bardia, A; Ciruelos, E; Cortes, J; Dalenc, F; Delaney, R; Fu, O; Jhaveri, KL; Lin, L; Loirat, D; Marmé, F; Pardo, PG; Rugo, HS; Schmid, P; Tolaney, SM; Trédan, O; Verret, W | 1 |
| Drier, SW; Ekwueme, DU; Fairley, TL; Gogate, A; Reeder-Hayes, KE; Rocque, GB; Rotter, J; Trogdon, JG; Wheeler, SB | 1 |
| Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X | 1 |
| Baroni, S; Capici, S; Cazzaniga, ME; Cerrito, MG; Cicchiello, F; Cogliati, V; Cordani, N; Maggioni, C; Malandrin, S; Pepe, FF; Riva, F | 1 |
| Beaumont, H; Chamorey, E; Faye, N; Hsieh, CY; Iannessi, A; Klifa, C | 1 |
| Badwe, R; Bajpai, J; Bhargava, P; Budrukkar, A; Desai, S; Ghosh, J; Gulia, S; Gupta, S; Joshi, S; Kannan, S; Nair, N; Pathak, R; Patil, A; Popat, P; Rath, S; Rathnasamy, N; Sarin, R; Shenoy, R; Shet, T; Wadasadawala, T | 1 |
| Bao, Y; Cai, L; He, X; Li, X; Wang, X; Zhang, Z | 1 |
| Huang, Y; Li, F; Wang, X; Wei, F; Yan, M; Yang, Y; Yang, Z | 1 |
| Anderson, J; Antonios, B; Deol, J; Gaikazian, S; Ghimire, B; Gupta, R; Gupta, S; Huben, M; Jaiyesimi, I; Jindal, V; Stender, M | 1 |
| Gao, C; Li, H; Li, L; Li, Y; Liu, D; Ma, X; Zhao, B; Zhao, Z | 1 |
| Burn, O; Dunton, K; Hancock, E; Paine, A; Petrou, M; Vondeling, G | 1 |
| Asleh, K; Ayala, F; Barrios, C; Bines, J; Cejalvo, JM; Gao, D; García-Sáenz, JÁ; Gómez, H; Goytain, A; Guerrero-Zotano, Á; Haba-Rodriguez, J; Herranz, J; Leung, S; Lluch, A; Martin, M; Nielsen, TO; Rojo, F; Ruiz-Borrego, M; Torrecillas, L; Torres, R; Wang, XQ | 1 |
| Dong, Z; Fang, Q; Wang, J; Wu, Y | 1 |
| Abramson, V; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, LA; Chien, AJ; Curigliano, G; DiGiovanna, MP; Feng, W; Gelmon, K; Hortobagyi, G; Hurvitz, SA; Krop, I; Lin, NU; Loi, S; Loibl, S; Mueller, V; Murthy, RK; Oliveira, M; Paplomata, E; Pegram, M; Ramos, J; Slamon, D; Winer, E; Zelnak, A | 1 |
| Gao, C; Li, B; Li, L; Li, Y; Liu, D; Ma, X; Zhao, B; Zhao, Z | 1 |
| Cai, Y; Li, W; Liu, X; Yuan, Y | 1 |
| Bechar, H; Belahcen, MJ; Cherif Chefchaouni, A; Nouibi, C; Rahali, Y | 1 |
| Antao, V; Lamarre, N; Montemurro, F; Peña-Murillo, C; Sanglier, T; Shim, J | 1 |
| Trapani, D | 1 |
| Fujita, S; Hattori, A; Hirano, A; Ishibashi, Y; Kamimura, M; Kitano, A; Kodera, A; Shiozawa, S; Yukawa, H | 1 |
| Antón, A; Belli, S; Bermejo, B; Bianco, R; Caballero, R; Ciruelos Gil, EM; Fernández-García, D; Fernandez-Serra, A; Formisano, L; Gil-Gil, M; Guerrero-Zotano, Á; Herranz, J; Liu, Y; López-Guerrero, JA; Margeli Vila, M; Martín, M; Muñoz-Mateu, M; Murillo, L; Nissenbaum, B; Pascual, J; Ruiz-Borrego, M; Turner, N; Zielinski, C | 1 |
| Chen, S; Fan, Y; Guan, X; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Zhang, P | 1 |
| Anders, CK; Lin, NU; Rader, RK; Sammons, SL | 1 |
| Gulmez, A | 1 |
| Huang, JF; Luo, PH; Mo, DC | 1 |
| Lin, NU | 1 |
| Huang, K; Lin, Y; Song, C; Yu, Y; Zhang, J | 1 |
| Bender, L; Fischbach, C; Kalish, M; Petit, T; Pflumio, C; Pierard, L; Trensz, P | 1 |
| Chai, Y; He, M; Jiang, M; Li, Q; Liu, J; Luo, Y; Ma, F; Wang, J; Wang, Z; Xu, B; Yuan, P | 1 |
| Dempsey, N; Mahtani, R; Sandoval, A | 1 |
| Bengala, C; Campadelli, E; Chini, C; Cinieri, S; Colleoni, M; Collovà, E; Cretella, E; Generali, D; Gianni, L; Loi, S; Montagna, E; Munzone, E; Orlando, L; Palleschi, M; Petrelli, F; Puglisi, F; Regan, MM; Ruepp, B; Shi, R; Zamagni, C | 1 |
| Araya, J; Hirano, S; Konishi, K; Nagabuchi, M; Ogino, J; Sakamoto, T | 1 |
| Alvarado-Miranda, A; Arce Salinas, CH; Arrieta, O; Galeana, PAC; Garza, CV; Guijosa, A; Lara-Medina, FU; Limón Rodríguez, JA; Muñoz-Montaño, WR; Sanchez Benitez, D; Zinser-Sierra, JW | 1 |
| Cao, J; Hu, X; Li, H; Li, L; Ling, X; Luo, J; Ouyang, Q; Pan, Y; Ren, L; Song, Z; Teng, Y; Wang, H; Wu, X; Xie, W; Xu, J; Zhang, L; Zhou, D | 1 |
| Fan, Y; He, M; Lan, B; Li, Q; Liu, J; Luo, Y; Ma, F; Mo, H; Wang, J; Wang, Z; Xu, B; Yuan, P; Zhang, P | 1 |
| Belau, A; Graf, H; Hofmann, M; Huober, J; Jackisch, C; Just, M; Krocker, J; Loibl, S; Nekljudova, V; Nitz, U; Reimer, T; Runnebaum, I; Schmatloch, S; Schmidt, M; Stickeler, E; Untch, M | 1 |
| Hayashi, M; Hirata, A; Iwamoto, M; Kimura, K; Morita, S; Takashima, Y; Terasawa, R | 1 |
| Cao, H; Chen, J; Deng, L; Li, Y; Wang, S; Wang, Y; Zhong, Y | 1 |
| Feng, X; Gao, S; Gao, X; Ge, TT; Pan, XJ; Shi, XG; Sun, P; Wang, TS; Wang, YK; Zuo, XM | 1 |
| Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J | 1 |
| Armstrong, A; Bannister, W; Conte, P; Degboe, A; Delaloge, S; Domchek, SM; Goessl, C; Hettle, R; Im, SA; Li, W; Masuda, N; Robson, M; Ruddy, KJ; Senkus, E; Tung, N; Xu, B | 1 |
| Gourd, E | 1 |
| García-Lozano, JA; González-Ramírez, RA; Ocampo-Candiani, J | 1 |
| Barba, M; Barchiesi, G; Ciliberto, G; Giulia, MD; Krasniqi, E; Massimiani, G; Pizzuti, L; Vici, P | 1 |
| Ding, T; Dong, L; Gu, XS; Li, JB; Ma, C; Xie, BJ; Zhu, LN; Zhu, ZN | 1 |
| Ban, L; Cui, X; Wang, D; Zhang, B; Zhang, X; Zhao, J | 1 |
| Corral de la Fuente, E; Fernández Abad, M; Martin Huertas, R; Martínez Jáñez, N; Serrano Domingo, JJ | 1 |
| Hassan, ZM; Khaligh, SG; Sirousazar, M; Taleblou, N | 1 |
| Chun, M; Yang, K | 1 |
| Chen, SC; Hsu, YH; Lin, YF; Shen, WC; Wang, CH | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Li, Q; Lin, S; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Ghilardi, M | 2 |
| Robert, M; Turner, N | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Alsarheed, A; Cobos, GA; LaChance, A; Laga, AC; LeBoeuf, N; Nelson, CA; Vleugels, RA | 1 |
| Goldstein, LJ; Varshavsky-Yanovsky, AN | 1 |
| Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY | 1 |
| Abramson, V; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Braga, S; Cameron, D; Carey, LA; Curigliano, G; Duhoux, FP; Feng, W; Gelmon, K; Greil, R; Hamilton, E; Hortobagyi, G; Hurvitz, SA; Jakobsen, E; Krop, I; Lin, NU; Loi, S; Loibl, S; Müller, V; Murthy, RK; Okines, A; Oliveira, M; Palanca-Wessels, MC; Paplomata, E; Pegram, M; Shachar, SS; Slamon, D; Walker, L; Winer, EP | 1 |
| Feliu, J; Ghanem, I; Higuera, O; Perez-Wert, P; Rodriguez-Salas, N; Viñal, D | 1 |
| Arimura, A; Baird, RD; Bonneterre, J; Campone, M; Cresti, N; Garcia-Corbacho, J; Italiano, A; Macpherson, IR; Posner, J; Rafii, S; Saggese, M; Spicer, J; Spiliopoulou, P; Takeda, Y | 1 |
| Anand, A; Brown, J; Brown, S; Coleman, R; Flanagan, L; Howell, S; Kendall, J; MacPherson, I; Palmieri, C; Rathbone, E; Reid, A; Twelves, C | 1 |
| Dokubo, I; Feinberg, B; Gajra, A; Kish, J; Lord, K; Wojtynek, J | 1 |
| Abdelhamid, T; El Desouky, ED; Khaled, H; Nassar, H; Omran, MA; Rashad, N; Shouman, SA | 1 |
| Bennett, M; Carter, G; McCauley, S; McNally, O; Rogers, KM | 1 |
| Ganesh, GNK; Pindiprolu, SKSS; Sanapalli, BKR; Singh, MK; Yele, V | 1 |
| Botticelli, A; Cerbelli, B; Lionetto, L; Marchetti, P; Roberto, M; Scagnoli, S; Simmaco, M | 1 |
| Lan, X; Li, S; Sun, Z; Xi, Y; Xu, S | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG | 1 |
| Hasegawa, K; Higashi, Y; Kaneko, J; Kazama, A; Kondo, I; Maejima, K; Maejima, S; Takatsuno, Y | 1 |
| Li, Q; Liao, W; Wang, F; Wang, X; Wu, Q; Zhang, M | 1 |
| Fu, P; Fu, Z; Huang, X; Jiang, Z; Jin, F; Li, J; Li, W; Li, Y; Sun, C; Wang, B; Wang, H; Wang, J; Wu, H; Yan, M; Yang, F; Yang, M; Yin, Y; Zeng, T; Zhang, J | 1 |
| Abramson, VG; Ayala-Peacock, DN; Chakravarthy, AB; Mayer, IA; Rexer, BN; Sherry, AD | 1 |
| Chiabudini, M; Decker, T; Falkenstein, J; Hagen, V; Hahn, A; Indorf, M; Klare, P; Kurbacher, CM; Maintz, C; Potthoff, K; Runkel, E; Sent, D; Söling, U; Vehling-Kaiser, U | 1 |
| Cao, J; Du, Y; Hu, X; Lin, M; Lin, Y; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhang, S | 1 |
| Ishiki, H; Satomi, E; Shimomura, A; Usui, Y | 1 |
| Abramson, VG; Chang, JC; Cox, N; Dees, EC; Dolan, ME; Fleming, GF; Forero, A; Hahn, OM; Hall, JP; Hoffman, PC; Huang, RS; Huo, D; Ingle, JN; Liu, MC; Merkel, DE; Morrow, PK; Nanda, R; Nath, A; Nurhussein-Patterson, A; O'Donnell, PH; Olopade, OI; Peppercorn, JM; Ratain, MJ; Rosner, GL; Rugo, HS; Storniolo, AM; Trubetskoy, V; Van Poznak, C; Wolff, AC | 1 |
| Aieta, M; Bordonaro, R; Borsellino, N; Bozza, G; Ciccarese, M; Cilenti, G; Cinieri, S; Colucci, G; Febbraro, A; Fedele, P; Forcignanò, R; Lorusso, V; Maiello, E; Orlando, L; Pisconti, S; Riccardi, F; Rinaldi, A; Romito, S; Saracino, V; Schiavone, P; Surico, G | 1 |
| Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A | 1 |
| Benson, JR; Dumitru, D; Jatoi, I | 1 |
| Goessl, C; Im, SA; Iwata, H; Li, W; Masuda, N; Ouyang, Q; Park, YH; Robson, M; Sohn, JH; Tseng, LM; Wu, W; Xu, B; Yeh, DC | 1 |
| De Santis, MC; La Rocca, E; Livi, L; Meattini, I; Vitullo, A | 1 |
| Aieta, M; Caliolo, C; Ciccarese, M; Cinefra, M; Cinieri, S; Colucci, G; Di Maio, M; Fedele, P; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pisconti, S; Prete, SD; Quaranta, A; Rizzi, D; Romito, S; Schiavone, P | 1 |
| Albuquerque, L; Guerreiro, C; Reimão, S | 1 |
| Dekker, TJA | 1 |
| Chen, J; Chen, Y; Dai, J; Gong, Y; Gu, D; Tang, C; Wei, J; Wei, X | 1 |
| Allegrini, G; Aout, M; Cortés, J; De Laurentiis, M; Diéras, V; Gelmon, K; Irahara, N; Lohrisch, C; Lorenzen, S; Montemurro, F; Oravcová, E; Perez-Garcia, JM; Ricci, F; Riera-Knorrenschild, J; Sakaeva, D; Serpanchy, R; Šufliarský, J; Thuss-Patience, P; Vidal, M; Wohlfarth, C | 1 |
| Bos, MEMM; Claessens, AKM; Erdkamp, FLG; Geurts, SME; Ibragimova, KIE; Tjan-Heijnen, VCG | 1 |
| Dodwell, D; Heudtlass, P; Johnston, S; Marshall, H; Murden, G; Oughton, JB; Passant, H; Pottinger, A; Price, C; Rizwanullah, M; Seligmann, JF; Velikova, G; Wright-Hughes, A | 1 |
| Augereau, P; Brain, E; Chenuc, G; D'Hondt, V; Dalenc, F; Delaloge, S; Eymard, JC; Ferrero, JM; Frenel, JS; Goncalves, A; Heudel, P; Ilie, S; Levy, C; Madranges, N; Mailliez, A; Mouret-Reynier, MA; Parent, D; Perol, D; Perrin, C; Petit, T; Robain, M; Sablin, MP; Simon, G; Uwer, L; Vermeulin, T | 1 |
| Kim, J; Nijhawan, RI; Schauder, DM | 1 |
| Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V | 1 |
| Andre, VAM; Carter, GC; Cortes, J; Dickler, MN; Dieras, V; Frenzel, M; Huang, YJ; Li, L; Li, XI; O'Shaughnessy, J; Patt, D; Rugo, HS; Sheffield, KM; Tolaney, SM; Wildiers, H; Yardley, DA; Zamora, E | 1 |
| Chatterjee, D; Hauser, R; Kaufman, PA; Kazmi, S; Raju, D | 1 |
| Assaf, JD; Escrivá-de-Romaní, S; Garrigós, L; Oliveira, M; Saura, C | 1 |
| Abdi, A; Alsaloumi, L; Basgut, B; Shawagfeh, S | 1 |
| Hao, C; Jia, Y; Li, S; Meng, W; Tong, Z; Xie, X; Zhang, J | 1 |
| Bardia, A; Beyerlin, K; Bossuyt, V; Edmonds, C; Ellisen, LW; Fell, GG; Isakoff, SJ; Jimenez, R; Johnson, A; Moy, B; Mulvey, TM; Specht, M; Spring, LM; Zangardi, M | 1 |
| Burstein, HJ; Parsons, HA | 1 |
| Masuda, N | 2 |
| Alba, E; Alvarez, I; Anton, A; Bermejo, B; Caballero, R; Calvo, L; Carrasco, E; Casas, MI; Chacón, JI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Garcia-Sáenz, JA; Gil-Gil, M; Guerrero-Zotano, A; Huang Bartlett, C; Huang, X; Kahan, Z; Koehler, M; Margeli, M; Martin, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Swift, C; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Goto, Y; Iwase, T; Tanaka, H | 1 |
| Berteloot, P; Beuselinck, B; Clement, P; Floris, G; Han, S; Janssen, H; Laenen, A; Menten, J; Nevelsteen, I; Neven, P; Punie, K; Remmerie, C; Smeets, A; Thijssen, S; Van Gorp, T; Van Nieuwenhuysen, E; Vergote, I; Weltens, C; Wildiers, H | 1 |
| Agostinetto, E; Ignatiadis, M | 1 |
| Chen, C; Chen, Q; Cheng, J; Cheng, Y; Feng, J; Geng, C; Gu, Y; Hu, X; Li, H; Li, W; Liu, J; Liu, Q; Lu, J; Luo, T; Ma, F; Ouyang, Q; Qin, S; Shen, K; Sun, T; Tong, Z; Wang, H; Wang, S; Wang, X; Wu, Y; Xu, B; Yan, M; Yang, J; Yin, Y; Yu, Z; Zhang, Q; Zhu, X; Zou, J | 1 |
| Barcenas, CH; Bartsch, R; Glück, S; Harbeck, N; Jackisch, C; Macedo, G; O'Shaughnessy, J; Palma, JD; Pistilli, B; Rugo, HS; Ruiz-Borrego, M | 1 |
| Ko, Y; Kuo, CN; Lin, YJ | 1 |
| Arnason, T; Hussein, N; Yim, C | 1 |
| Goodwin, A; Im, SA; Kim, SB; Lanzalone, S; Lee, KH; Sohn, J; Usari, T | 1 |
| Isaacs, C; O'Regan, R; O'Shaughnessy, JA | 1 |
| Ballman, KV; Chen, B; De Silva, C; Dueck, AC; Goetz, MP; Haddad, TC; Haluska, P; He, J; Hopkins, JO; Linden, H; Northfelt, D; O'Sullivan, CC; Perez, EA; Sparano, JA; Tenner, KS | 1 |
| Huang, C; Wang, J; Zhang, H; Zhang, Y | 1 |
| Alarcon, J; Ang, PCS; Bebchuk, J; Bose, R; Brufsky, A; Bryce, R; Chan, N; Chu, SC; Delaloge, S; Fagnani, D; Gradishar, W; Hurvitz, SA; Kalmadi, S; Keyvanjah, K; Kim, SB; Kwong, A; Lee, KS; Moy, B; Oestreicher, N; Oliveira, M; Ow, SGW; Ryvo, L; Saura, C; Silverman, P; Zhang, B | 1 |
| Bi, XW; Hua, X; Yuan, ZY | 1 |
| Akhtar, N; Chakrabarti, D; Kumar, V | 1 |
| Du, F; Yuan, P | 1 |
| Ahmed, KA; Czerniecki, BJ; Etame, AB; Figura, NB; Forsyth, PA; Han, HS; Kushchayev, S; Liu, JKC; Mills, MN; Naz, A; Oliver, DE; Robinson, TJ; Soliman, HH; Thawani, C; Vogelbaum, MA; Walker, C; Yu, HM | 1 |
| Banks, PD; Bulsara, MK; Hoon, SN; Lau, PK; Redfern, AD; White, AM | 1 |
| Ito, KI; Kamijo, S; Oba, T; Shibata, T; Tanimoto, K; Watanabe, T | 1 |
| Chilà, G; Galizia, D; Geuna, E; Guarini, V; Montemurro, F | 1 |
| Aithal, S; Arkenau, HT; Block, M; Boyle, F; Brenner, A; Cameron, D; Cancel, M; Cold, S; Colleoni, M; Crouzet, L; Curigliano, G; Curtit, E; DeBusk, K; Fehrenbacher, L; Feng, W; Ferrario, C; Gelmon, K; Hahn, O; Hamilton, E; Harder Brix, E; Iqbal, N; Jakobsen, E; Mueller, V; Muñoz-Mateu, M; Paplomata, E; Poosarla, T; Ramos, J; Siadak, M; Stringer-Reasor, E; Wardley, A; Zelnak, A | 1 |
| Bagnardi, V; Cancello, G; Cazzaniga, ME; Colleoni, M; Malengo, D; Montagna, E; Munzone, E; Negri, M; Pagan, E; Peruzzotti, G; Salè, EO; Sangalli, C; Veronesi, P; Viale, G | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Aouthmany, M; Gehlhausen, JR; Katona, TM; Strausburg, MB; Turner, MJ | 1 |
| Amadori, D; Andreis, D; Bravaccini, S; Bronte, G; Cecconetto, L; Donati, C; Farolfi, A; Fedeli, A; Maltoni, R; Rocca, A; Schirone, A; Serra, P | 1 |
| Chen, G; Dong, J; Guo, J; Guo, Z; Liu, M; Yao, G; Ye, C | 1 |
| Amir, E; Cescon, DW; Ethier, JL; Natori, A | 1 |
| Chen, M; Guardino, E; Sheth, S; Svahn, T; Vidal, GA | 1 |
| Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Arima, N; Hasegawa, S; Kai, Y; Katayama, K; Koga, T; Kurashita, K; Mitsuyama, S; Nishimura, R; Ohi, Y; Okumura, Y; Saimura, M; Saito, T; Shimada, K; Tamura, K; Tanaka, M; Tanaka, T; Teraoka, M; Todoroki, H; Toh, U; Toyoshima, S | 1 |
| Bachelot, T; Beroud, C; Bobin-Dubigeon, C; Bonneterre, J; Boyer, JC; Chaigneau, L; Chamorey, E; Château, Y; Chatelut, E; Desvignes, JP; Dieras, V; Dohollou, N; Etienne-Grimaldi, MC; Evrard, A; Ferrand, C; Ferrero, JM; Follana, P; Goncalves, A; Largillier, R; Llorca, L; Mbatchi, L; Meijer, J; Merlin, JL; Milano, G; Mousseau, M; Pinguet, F; Pivot, X; Roché, H; Romieu, G; Salgado, D; Servent, V; Thomas, F; van Kuilenburg, A | 1 |
| Dormont, D; Galanaud, D; Law-Ye, B; Leclercq, D; Obadia, M; Psimaras, D; Pyatigorskaya, N; Sahli-Amor, M; Wasserman, J | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Cancello, G; Colleoni, M; Contaldo, F; Maisonneuve, P; Montagna, E; Pruneri, G; Vingiani, A | 1 |
| Aogi, K; Im, SA; Im, YH; Iwata, H; Jeong, J; Kim, A; Kim, SB; Kuroi, K; Lee, ES; Lee, SJ; Masuda, N; Ohashi, Y; Ohno, S; Ohtani, S; Park, BW; Park, KH; Sasano, H; Takao, S; Toi, M; Yanagita, Y; Yokota, I | 1 |
| Burki, TK | 1 |
| Baars, A; de Mol, P; Kok, WEM; Koopman, M; Kwakman, JJM; Punt, CJA; van Zweeden, AA | 1 |
| DeMichele, A; Patel, SA | 1 |
| Metzger-Filho, O; Winer, EP | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Petrelli, F; Tomasello, G | 1 |
| Allred, J; Carey, L; Cohen, H; Hopkins, JO; Hudis, C; Hurria, A; Jatoi, A; Lafky, JM; Mandelblatt, J; Muss, HB; Partridge, A; Winer, E | 1 |
| Boven, E; Guchelaar, HJ; Honkoop, AH; Lam, SW; Peters, GJ; van der Noort, V; van der Straaten, T | 1 |
| Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
| Masuda, N; Ohashi, Y; Toi, M | 1 |
| Hizal, M; Şendur, MAN; Yalçin, B | 1 |
| Burdette-Radoux, S; Ruades Ninfea, JI; Wood, ME | 1 |
| Dees, EC; Henderson, GE; Reeder-Hayes, KE; Roberts, MC | 1 |
| Arriaga, L; Babiera, GV; Buchholz, TA; Cohen, EN; Fang, P; Gao, H; Hoffman, K; Le-Petross, H; Middleton, LP; Perkins, GH; Reuben, JM; Smith, BD; Strom, EA; Tereffe, W; Valero, V; Woodward, WA | 1 |
| Ge, L; Li, A; Li, P; Li, W; Li, Y | 1 |
| Anders, CK; Chao, YL | 1 |
| Hu, EH; Keung, YK; Yu, D; Zurayk, M | 1 |
| Andrés-Lencina, JJ; Aragón-Miguel, R; Calleja-Algarra, A; Maroñas Jiménez, L; Monsálvez Honrubia, V; Ortiz Romero, PL; Prieto Barrios, M; Velasco-Tamariz, V | 1 |
| Al-Batran, SE; de Wit, M; Dorn, J; Harbeck, N; Honecker, F; Jäger, E; Kreienberg, R; Müller, L; Otremba, B; Saupe, S; Schmidt, M; Schnabel, C; Waldenmaier, D; Warm, M; Wedding, U | 1 |
| Joensuu, H; Lindman, H | 1 |
| Cubero, D; de Melo Sette, CV; Del Giglio, A; Fonseca, F; Martins, JC; Mutti, H; Scontre, VA | 1 |
| He, Q; Jiang, Y; Li, S; Shi, C; Yang, X | 1 |
| Anders, CK; Carey, LA; Dees, EC; Hu, Z; Kornblum, ZA; Marcom, PK; McRee, AJ; Moore, DT; Perou, CM; Phipps, R; Reeder-Hayes, K; Weck, KE; Zamboni, WC | 1 |
| Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A | 1 |
| Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J | 1 |
| Cortes, J; Perez-Garcia, J | 1 |
| Gwin, WR; Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, Q; Wang, X; Zhou, X | 1 |
| Bennett, DD; Burkard, ME; Shah, RA | 1 |
| Arslan, FZ; Aybay, MN; Cengiz, A; Öner, V; Sarıcı, SF | 1 |
| Gligorov, J; Pivot, X; Richard, S | 1 |
| Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Izu, A; Koshinaga, T; Kubota, H; Makishima, M; Sakurai, K; Sugitani, M; Suzuki, S | 1 |
| Bergh, J; Brage, SE; Carlsson, L; Einbeigi, Z; Fernö, M; Foukakis, T; Hatschek, T; Linderholm, B; Loman, N; Lorent, J; Lövrot, J; Malmberg, M; Matikas, A; Skoog, L; Suzuki, C; Tobin, N; Zerdes, I | 1 |
| Aapro, M; Bondarenko, I; Campone, M; Krishnamurthy, S; Lebedeva, L; Martin, M; Roman, L; Sakaeva, D; Vedovato, JC | 1 |
| Ahn, JH; Im, SA; Jung, KH; Kim, HJ; Kim, JH; Kim, SB; Kim, TY; Lee, KH; Lee, KS; Lee, S; Nam, BH; Park, IH; Park, KH; Park, YH; Ro, J; Sim, SH; Sohn, JH | 1 |
| Ozaki, A; Takita, M; Tanimoto, T | 1 |
| Catanese, B; Chin, C; Connolly, EP; Kalinsky, K; Lee, SM; Liu, YL; Zhan, S | 1 |
| Arumí, M; Bellet, M; Escrivá-de-Romaní, S; Saura, C | 1 |
| Friberg, LE; Girish, S; Jin, JY; Karlsson, MO; Li, C; Lum, BL; Quartino, A; Schindler, E; Wang, B | 1 |
| DeMichele, A; Diab, S; Geschwindt, R; Jiang, W; Kalinsky, K; Kennealey, G; Ma, CX; O'Shaughnessy, J; Richards, P; Rugo, HS; Steis, R; Wright, GS; Yardley, DA | 1 |
| Aogi, K; Fukuoka, J; Ito, Y; Kawabata, H; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Saeki, T; Sakai, K; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tsurutani, J; Yamanaka, T | 1 |
| Cherdyntseva, N; Choinzonov, E; Deryusheva, I; Frolova, I; Ibragimova, M; Kazantseva, P; Kzhyshkowska, J; Larionova, I; Litviakov, N; Slonimskaya, E; Tsyganov, M | 1 |
| Gianni, L | 1 |
| Borges, VF; Chamberlain, M; Chaves, J; Conlin, A; Gray, T; Hamilton, E; Murthy, R; Vo, A | 1 |
| Domchek, SM | 1 |
| Blau, S; Burris, H; de Boer, RH; Ejlertsen, B; Ewertz, M; Fan, J; Hurvitz, S; Jerusalem, G; Kovalenko, E; Landherr, L; Louveau, AL; Noel-Baron, F; Özgüroglu, M; Taran, T; Yardley, DA | 1 |
| Fujiwara, Y; Iizumi, S; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K | 1 |
| Bourmaud, A; Chauvin, F; Colomban, O; Freyer, G; Girard, P; Guitton, J; Henin, E; Le Saux, O; Maraval-Gaget, R; Ranchon, F; Regnier, V; Rioufol, C; Schwiertz, V; Tod, M; Trillet-Lenoir, V; You, B | 1 |
| Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A | 1 |
| Bae, S; Banchereau, J; Banchereau, R; Blankenship, D; Brookes, HM; Cepika, AM; Chung, CH; George, J; Kim, KI; Lavecchio, E; Levin, MK; Marches, F; Martinek, J; O'Shaughnessy, J; Obermoser, G; Oxley, KL; Palucka, AK; Pascual, V; Smith, JL; Snipes, GJ; Turner, J; Wang, X; Wu, TC; Xu, K; Young, RR; Zurawski, S | 1 |
| Daniels, B; Girosi, F; Houssami, N; Kiely, BE; Lord, SJ; Pearson, SA; Tervonen, H | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG; van der Sangen, MJC; van Druten, E; van Warmerdam, LJC | 1 |
| Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J | 1 |
| Huang, Q; Jiang, Y; Li, Q; Li, S; Liu, J; Wei, W; Yang, H | 1 |
| Blair, HA | 1 |
| Ivanova, D; Jia, XQ; Lei, L; Li, JW; Liu, GY; Zuo, WJ | 1 |
| Cui, S; Sun, Y; Ye, M; You, D; Zhao, Q | 1 |
| Jiang, Z; Lan, L; Li, L; Pan, Z; Yang, Y; Yue, Z | 1 |
| Brinch, CM; Ekblad, L; Hermann, KL; Holm, VH; Jensen, BK; Jensen, BV; Larsen, FO; Lindgaard, SC; Michelsen, H; Nelausen, KM; Nielsen, DL; Nørgaard, HH; Soerensen, PG; Theile, S | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Hu, S; Huang, J; Li, C; Li, Q; Luo, Y; Ma, F; Sun, X; Wang, J; Wu, S; Xu, B; Zhang, P | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C | 1 |
| Ding, D; Han, J; Hu, H; Huang, J; Jiang, Q; Liao, M; She, L; Yao, L | 1 |
| Anders, CK; Blackwell, KL; Burns, R; Componeschi, KP; Connolly, RM; Cotter, CM; Cropp, AM; Freedman, RA; Gelman, RS; Ibrahim, N; Jankowitz, RC; Krop, IE; Lin, NU; Marte, JM; Melisko, ME; Moy, B; Moynihan, TJ; Nangia, J; Niravath, P; O'Sullivan, CC; Parsons, HA; Pohlmann, PR; Puhalla, SL; Rimawi, MF; Silvestri, K; Smith, KL; Tung, N; Van Poznak, CH; Winer, EP; Wolff, AC | 1 |
| Hurvitz, SA | 1 |
| Aguirre, LE; Mahtani, R; Ramdial, JL; Torres, A; Vogel, CL | 1 |
| Stirrups, R | 1 |
| Bradley, CA | 1 |
| de Stanchina, E; Fleisher, M; Kemeny, MM; Li, BT; Morikawa, A; Norton, L; Patil, S; Pentsova, E; Seidman, AD; Tang, K; Van Poznak, C | 1 |
| Ciruelos, E; de la Haba-Rodriguez, J; Gavilá, J; Pérez-García, JM; Rodríguez, A | 1 |
| Adachi, E; Egawa, G; Kabashima, K | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Lan, B; Li, Q; Luo, Y; Ma, F; Wang, J; Xing, P; Xu, B; Yi, Z; Yuan, P; Zhang, P; Zhang, Y; Zhong, D; Zhu, X; Zou, J | 1 |
| Chang, L; Chen, S; Futreal, A; Guan, X; Guan, Y; Huang, J; Husain, H; Li, C; Li, Q; Liao, Z; Ma, F; Qian, H; Xia, X; Xu, B; Yang, L; Yi, X; Yi, Z; Zhang, J; Zhu, W | 1 |
| André, T; Barin-Le-Guellec, C; Bouché, O; Boyer, JC; Carni, P; Ciccolini, J; Delaloge, S; Étienne-Grimaldi, MC; Faroux, R; Guigay, J; Le Malicot, K; Legoux, JL; Loriot, MA; Malka, D; Masskouri, F; Michel, P; Seitz, JF; Thariat, J; Thomas, F | 1 |
| Ay, E; Ersez, MS; Hepokur, C; Kariper, İA; Kuruca, SE; Mısır, S; Tunoğlu, S; Yaylım, İ; Zeybek, Ü | 1 |
| Berry, DA; Burstein, HJ; Carey, L; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Hurria, A; Jatoi, A; Kartcheske, PA; Kornblith, AB; Liu, H; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Polley, MC; Sutton, LM; Theodoulou, M; Winer, EP; Wolff, AC | 1 |
| Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT | 1 |
| Fujiuchi, N; Misumi, M; Nakamiya, N; Osaki, A; Saeki, T; Shigekawa, T; Sugitani, I; Sugiyama, M; Takeuchi, H | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Schaller, G | 1 |
| El Mahdy, MM; El-Arab, LR; Swellam, M | 1 |
| Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M | 1 |
| Ballman, KV; Cohen, HJ; Freedman, RA; Hudis, CA; Hurria, A; Keating, NL; Kimmick, GG; Kornblith, AB; Mandelblatt, J; Muss, HB; Pitcher, B; Winer, EP | 1 |
| Ellis, CE; Fujii, H; Gagnon, RC; Iwata, H; Katsura, K; Masuda, N; Mukai, H; Nakamura, S; Nishimura, Y | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Chan, A; Conte, PF; Espie, M; Ganju, V; Gil, MG; Llombart, A; Majois, F; Petruzelka, L; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Ariad, S; Geffen, DB; Geva, S; Lazarev, I | 1 |
| Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R | 1 |
| Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Saarni, O; Tanner, M; Villman, K | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Fang, P; Ji, TF; Liu, H; Shi, WW; Yang, B; Yang, JL; Zhu, YY | 1 |
| Alcazar-González, GA; Barrera-Saldaña, HA; Calderón-Garcidueñas, AL; Castruita-Avila, AL; Cerda-Flores, RM; Escorza-Treviño, S; Garza-Rodríguez, ML; González-Guerrero, JF; le Brun, S; Olano-Martin, E; Rubio-Hernández, G; Simon-Buela, L | 1 |
| Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Aogi, K; Bando, H; Chow, LW; Fakhrejahani, E; Hisamatsu, K; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Kuroi, K; Masuda, N; Morimoto, T; Nakamura, S; Nakayama, T; Ohno, S; Sasano, H; Sato, N; Takahashi, F; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H; Yoshida, N | 1 |
| Bruining, A; Doll, PK; Gilhuijs, KG; Linn, SC; Lips, EH; Loo, CE; Mandjes, IA; Rigter, LS; Rodenhuis, S; Sonke, GS; van Werkhoven, E; Vrancken Peeters, MJ; Warnars, HA; Wesseling, J | 1 |
| Akça, Z; Büyükçelik, A; Erden, A; Mutlu, H | 1 |
| Li, Z; Yang, J; Zhang, F | 1 |
| Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M | 1 |
| Blakely, LJ; Houts, AC; Schwartzberg, LS; Somer, BG; Stepanski, EJ; Walker, MS; Wang, G; Wheeler, BM | 1 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Athanasiadis, A; Cantara, G; Kaufmann, M; Klag, T; Ong, P; Sechtem, U | 1 |
| Akbari Javar, H; Farjam, AS; Ibrahim Noordin, M; Kadivar, A; Kamalidehghan, B; Taghizadeh Davoudi, E | 1 |
| Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JW; Schrama, JG; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| Bannerji, R; Jou, YM; Joy, AA; Mita, A; Mita, MM; Sankhala, K; Shapiro, CL; Small, K; Statkevich, P; Yao, SL; Zhang, D; Zhu, Y | 1 |
| Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T | 1 |
| Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E | 1 |
| Bellon, J; Brock, J; Come, SE; Golshan, M; Guo, H; Jeong, J; Krop, IE; Morganstern, D; Tolaney, SM; Winer, EP | 1 |
| Baselga, J; Bosserman, L; Gómez, H; Li, RK; Mukhopadhyay, P; Sparano, JA; Vahdat, LT; Valero, V; Vrdoljak, E | 1 |
| Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q | 1 |
| Braun, JJ; de Graaf, H; de Groot, SM; de Jongh, FE; Hamaker, ME; Los, M; Maartense, E; Nortier, JWR; Seynaeve, C; Smorenburg, CH; van Leeuwen-Stok, AE; van Tinteren, H; Wymenga, AN | 1 |
| Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE | 1 |
| Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T | 1 |
| Railey, E; Sledge, GW; Smith, ML; White, CB | 1 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K | 1 |
| Cao, KI; Kirova, YM | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Hayashi, M; Hironaka, H; Morita, N; Orita, M | 1 |
| Ibayashi, Y; Jotoku, H; Takahashi, M; Takasaki, M; Tanaka, H; Watanabe, K | 1 |
| Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M | 1 |
| Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M | 1 |
| Brooks, C; Gibson, O; Grainger, L; Larsen, M; Love, SB; Shanyinde, M; Shearwood, V; Tarassenko, L; Waters, R; Weaver, A; Young, AM | 1 |
| Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L | 1 |
| Cserni, G; Csörgő, E; Kelemen, G; Kővári, B; Lázár, P; Nyári, T; Rusz, O; Vörös, A | 1 |
| Ahn, E; Ambros, T; Aruna, M; Kronish, L; Mahtani, RL; Montero, AJ; Vogel, CL; Zaravinos, J; Zeichner, SB | 1 |
| Drzymała, M; Golon, K; Karczmarek-Borowska, B | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 1 |
| Adachi, Y; Aoshima, K; Asano, M; Funahashi, Y; Kawano, S; Kimura, T; Matsui, J; McCracken, PJ; Nomoto, K; Oda, Y; Okamoto, K; Ozawa, Y; Semba, T; Tizon, X; Tohyama, O; Uehara, T; Uesugi, M; Watanabe, H | 1 |
| Guo, X; Jiao, S; Jing, F; Li, J; Linghu, R; Liu, M; Yang, J; Zhu, Y | 1 |
| Ballman, KV; Cohen, HJ; Hudis, C; Hurria, A; Kimmick, GG; Klepin, HD; Kornblith, AB; Muss, HB; Pitcher, BN; Winer, EP | 1 |
| Bang, YJ; Cha, Y; Han, SW; Han, W; Im, SA; Kim, TY; Noh, DY; Oh, DY; Park, IA; Seol, H | 1 |
| Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK | 1 |
| Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Bayraktar, S; de Snoo, F; Glück, S; Royce, M; Stork-Sloots, L | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tokuyama, Y; Tsurushima, M; Uchiyama, K | 1 |
| Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S | 1 |
| Alba, E; Bines, J; Cortes, P; Costa, R; de Ducla, S; Doval, D; Freudensprung, U; Gligorov, J; Gupta, V; Mustacchi, G; Pierga, JY; Srock, S | 1 |
| Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B | 1 |
| Shawky, H; Tawfik, H | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B | 1 |
| Brufsky, A | 1 |
| Dragun, AE; Dunlap, NE; Jain, D; Meena, RA; Quillo, AR; Riley, EC; Shaughnessy, JN | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Friedrich, M; Kummer, S; Terjung, A | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Fuxius, S; Hahn, LJ; Hurst, U; Lerchenmüller, C; Luhn, B; Müller, V; Soeling, U; Steffens, CC; Vehling-Kaiser, U; Wohlfarth, T; Zaiss, M | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K | 1 |
| Alonso, R; Caballero, R; Calvo, L; Caronia, D; Carrasco, E; Casado, A; Chacón, JI; Constenla, M; De la Haba, J; De la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Guerra, E; Heras, L; Hernando, B; Jimeno, MÁ; Lluch, A; Martín, M; Martínez, N; Muñoz, M; Pita, G; Ramos, M; Ruíz-Borrego, M; Zamora, P | 1 |
| Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B | 1 |
| Awada, A; Cortes, J; Dutcus, CE; He, Y; Kaufman, PA; Olivo, MS; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Quintana-Quintana, M; Segura-González, M | 1 |
| Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L | 1 |
| Cao, J; Hu, X; Liu, Z; Lv, F; Shao, Z; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, S; Zhao, X | 1 |
| Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D | 1 |
| Balasubramanian, S; Blum, JL; Brooks, B; Cao, Y; Hoke, N; Levin, MK; O'Shaughnessy, J; Palma, N; Palmer, G; Pippen, J; Ramos, C; Ross, JS; Wang, K; Yelensky, R | 1 |
| Chavarri-Guerra, Y; Soto-Perez-de-Celis, E | 1 |
| Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N | 1 |
| Allred, JB; Ballman, K; Cohen, HJ; Gajra, A; Gralow, J; Hopkins, JO; Hurria, A; Jatoi, A; Kottschade, L; Lafky, J; Muss, H; Wolff, A | 1 |
| Ahn, JS; Choi, MK; Hong, JY; Im, YH; Jung, HA; Lee, SJ; Park, YH | 1 |
| Blum, JL; Brooks, R; Brownstein, C; Hoersch, S; Holmes, FA; Jones, S; Koeppen, H; Krekow, L; Lackner, MR; Lindquist, D; McIntyre, K; O'Shaughnessy, J; Paul, D; Pippen, J; Rivera, R; Sedlacek, S; Stokoe, C; Vukelja, S; Xiao, Y | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Alfer, J; Burchardi, N; Conrad, B; Decker, T; Denkert, C; Eidtmann, H; Eiermann, W; Hackmann, J; Huober, J; Jackisch, C; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Potenberg, J; Reimer, T; Simon, E; Stickeler, E; Thomssen, C; von Minckwitz, G | 1 |
| Moser, A; Piwko, C; Pollex, E; Prady, C; Yunger, S | 1 |
| Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F | 1 |
| Bourmaud, A; Chauvin, F; Colomban, O; Freyer, G; Girard, P; Guitton, J; Hamant, C; Henin, E; Ranchon, F; Regnier, V; Rioufol, C; Tinquaut, F; Tod, M; Trillet-Lenoir, V; You, B | 1 |
| Figoni, W; Ikenishi, M; Konishi, Y; Kuroda, A; Matsuda, T; Matsuyama, K; Nakao, M; Nakatsuka, E; Ohtori, T; Satoh, H; Sawada, Y; Takeuchi, M; Tsukazaki, H; Ueda, M | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Guan, J; Lin, Y; Mao, F; Sun, Q; Zhang, X; Zhou, Y | 1 |
| Ben-Baruch, NE; Bose, R; Ellis, MJ; Kavuri, SM; Ma, CX | 1 |
| Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A | 1 |
| Feng, X; Gao, S; Huang, L; Liu, G; Pei, G; Yin, W | 1 |
| Berrak, E; Hoffman, AD; Jones, VE; McIntyre, K; O'Shaughnessy, J; Smith, JW; Song, JX; Vukelja, S | 1 |
| Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A | 1 |
| Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y | 1 |
| Ahn, JS; Awada, A; Cortes, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Bonnefoi, H; Grellety, T; Italiano, A; Robert, J; Soubeyran, I | 1 |
| Awada, A; Cortes, J; Forsythe, A; Hudgens, S; Kaufman, PA; McCutcheon, S; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Bernardo, A; Danesi, R; Del Re, M; Michelucci, A; Palumbo, R; Quaquarini, E; Simi, P; Sottotetti, F | 1 |
| Fang, A; Guérin, A; Hao, Y; Kageleiry, A; Koo, V; Li, N; Peeples, M; Wu, EQ | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Inbar, MJ; Kahan, Z; Lang, I; Messinger, D; Stemmer, SM; Vrbanec, D; Zielinski, C | 1 |
| Beurdeley, A; Bièche, I; Cairo, S; Château-Joubert, S; Déas, O; Decaudin, D; Depil, S; Fontaine, JJ; Gaston, J; Judde, JG; Lassalle, M; Legrier, ME; Marangoni, E; Poupon, MF; Roman-Roman, S; Servely, JL; Thuleau, A; Tucker, GC; Vacher, S; Yvonnet, V | 1 |
| Adam, EJ; Doss, S; Elsada, A; Robertson, J | 1 |
| Bian, L; Jiang, Z; Li, W; Song, S; Wang, T; Zhang, H; Zhang, S; Zhou, J | 1 |
| Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG | 1 |
| Bruzzese, F; Budillon, A; D'Angelo, G; Di Gennaro, E; Franco, R; Leone, A; Roca, MS; Russo, D; Scogliamiglio, G; Terranova-Barberio, M; Vitagliano, C; Zotti, AI | 1 |
| Cirrincione, CT; Cohen, HJ; Gralow, J; Hurria, A; Jatoi, A; Lichtman, SM; Magrinat, G; Morganstern, DE; Muss, HB; Theodoulou, M; Wolff, AC | 1 |
| Darb-Esfahani, S; Denkert, C; Eidtmann, H; Fasching, PA; Furlanetto, J; Hartmann, A; Huober, J; Jackisch, C; Klimowicz, A; Lederer, B; Loibl, S; Mehta, K; Pfitzner, B; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Cui, S; Wang, L; Zhang, C | 1 |
| Amano, S; Enomoto, K; Ono, Y; Sakurai, K | 1 |
| Cao, L; Chen, L; Hu, X; Liu, M; Yao, G; Ye, C | 1 |
| Floris, G; Jongen, L; Neven, P; Paridaens, R; Wildiers, H | 1 |
| Baudot, A; Bosacki, C; Bourmaud, A; Chauvin, F; Collard, O; Jacquin, JP; Moine, V; Moriceau, G; Muron, T; Oriol, M; Pacaut, C; Regnier-Denois, V; Saban-Roche, L; Tinquaut, F | 1 |
| Busies, S; Decker, T; Depenbusch, R; Hegewisch-Becker, S; Koehler, A; Lerchenmueller, C; Marschner, N; Steffens, CC; Welt, A | 1 |
| Bounthavong, M; Chen, T; Nguyen, CP; Wong, SF | 1 |
| de la Cruz Merino, L; Marcos Rodríguez, JA; Romero Carreño, E; Santana Martínez, S | 1 |
| Muss, HB; Nishijima, TF; Suzuki, M | 1 |
| Berdnik, AV; Bulychkin, PV; Bykova, YB; Fedoseenko, DI; Gutnik, RA; Medvedev, SV; Mikhina, ZP; Moskvina, EA; Naskhletashvili, DR; Romanov, DS; Tkachev, SI; Trofimova, OP; Yazhgunovich, IP | 1 |
| Bekyashev, AK; Belov, DM; Gasparyan, TG; Medvedev, SV; Moskvina, EA; Naskhletashvili, DR | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Ooe, A; Suganuma, Y | 1 |
| Chen, XL; Du, F; Fan, Y; Hong, RX; Li, Q; Luo, Y; Wang, JY; Xu, BH | 1 |
| Nakai, M; Takei, H; Uchida, E; Yamashita, K; Yanagihara, K | 1 |
| Ballman, K; Calfa, C; Clynes, R; Erskine, CL; Kemp, KP; Knutson, KL; Mittendorf, EA; Northfelt, D; Norton, N; Pegram, M; Perez, EA; Shreeder, B; Tan, W; Tenner, KS; Yeramian, P | 1 |
| Barni, S; Bisagni, G; Bogina, G; Duranti, S; Fabi, A; Fiorio, E; Foglietta, J; Gori, S; Inno, A; Leonardi, V; Lunardi, G; Marchetti, F; Montemurro, F; Pavese, I; Pellegrino, A; Rossi, V; Santini, D; Saracchini, S; Turazza, M; Vici, P; Zambelli, A | 1 |
| Abramson, V; Forero, A; Huang, RS; LaCroix, B; Lenkala, D; Morrison, G; Morrow, PK; Nanda, R; O'Donnell, PH; Rugo, HS; Van Poznak, C; Ziliak, D | 1 |
| Aktaş, A; Birdal, C; Elmas, ÖF; Kızılyel, O; Metin, MS | 1 |
| Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Lim, XY; Loh, M; Soo, RA; Soong, R; Syn, N; Tan, SH; Wang, L; Wong, AL; Yong, WP; Zee, YK | 1 |
| Dackus, GM; Linn, SC; Marchetti, S; Schellens, JH; Schouten, PC; Sonke, GS; van Tinteren, H | 1 |
| Awada, A; Binder, TA; Cortes, J; Jove, M; Kaufman, PA; O'Shaughnessy, JA; Olivo, M; Perez, EA; Song, J; Twelves, C; Yelle, L | 1 |
| Lemmo, W | 1 |
| Gonzalez-Martin, A; Kim, SB; Krop, IE; Lysbet de Haas, S; Smitt, M; Wildiers, H; Yu, R | 1 |
| Milano, G | 1 |
| Augereau, P; Bourien, H; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A | 1 |
| Li, J; Ren, J; Sun, W | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Dank, M; Eniu, A; Greil, R; Inbar, M; Kahán, Z; Láng, I; Melichar, B; Messinger, D; Nisenbaum, B; Petruzelka, L; Pienkowski, T; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Di, L; Li, W; Liu, W; Qiu, R; Tang, L; Tian, F; Tong, Z; Wang, Y; Xu, B; Yang, J; Zhang, P | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Bae, YH; Kang, JH; Le, QA | 1 |
| Cao, Y; Jiang, JY; Jin, F; Liu, H; Ma, B; Mao, XY; Wang, YY | 1 |
| Hong, D; Hu, H; Liu, L; Lou, Y; Wang, Q; Zeng, S; Zheng, J | 1 |
| Bidoli, P; Capici, S; Cazzaniga, ME; Cicchiello, F; Cortinovis, D; Digiacomo, N; Porcu, L; Riva, F; Torri, V | 1 |
| Goh, BC; Lee, SC; Syn, N; Yong, WP | 1 |
| Anchisi, S; Bärtschi, D; Bernhard, J; Bigler, M; Borner, M; Cathomas, R; Hasler-Strub, U; Küng, M; Matter-Walstra, K; Müller, A; Na, KJ; Rauch, D; Rochlitz, C; Rordorf, T; Ruhstaller, T; Trojan, A; Vetter, M; von Moos, R; Wicki, A; Winterhalder, R; Zaman, K | 1 |
| Li, XY; Lin, SL; Xu, QN; Zhang, ZC | 1 |
| Biraghi, E; Cazzaniga, ME; Ciccarese, M; Cicchiello, F; Cortesi, L; Della Torre, S; Ferzi, A; Gambaro, AR; Giordano, M; Legramandi, L; Nicolini, M; Rulli, E; Scaltriti, L; Verusio, C; Villa, F; Zanlorenzi, L | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Büdi, L; Erfán, J; Győrfy, K; Hitre, E; Horváth, Z; Kahán, Z; Kocsis, J; Kószó, R; Landherr, L; Máhr, K; Pajkos, G; Pápai, Z; Sántha, D | 1 |
| Larsen, FO; Nielsen, DL; Polk, A; Schou, M; Shahmarvand, N; Vaage-Nilsen, M; Vistisen, K | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Lian, B; Mo, Q; Qin, Q; Tan, Q; Wei, C; Yang, W | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Cancello, G; Cardillo, A; Colleoni, M; Esposito, A; Goldhirsch, A; Iorfida, M; Lai, A; Maisonneuve, P; Mazza, M; Montagna, E; Munzone, E; Palazzo, A; Sciandivasci, A | 1 |
| Dalal, RP; Gao, L; Garcia, AA; Gradishar, W; Joy, AA; Kauh, J; Khatcheressian, J; Layman, R; Miller, K; Rodriguez, G; Salkeni, MA; Sparano, J; Tang, S; Vahdat, LT; Ward, P; Yardley, DA | 1 |
| Cascinu, S; Fontana, A; Maur, M; Omarini, C; Pettorelli, E; Piacentini, F | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Cowman, S; Stebbing, J; Tuthill, M | 1 |
| Cameron, DA; Stein, S | 1 |
| Batista, N; Cruz, J; Dómine, M; Estévez, LG; León, A; Provencio, M; Rodríguez, M; Sánchez-Rovira, P; Velasco, A | 1 |
| Abdullah, S; Doliny, P; Gautam, U; Gluck, S; Hurley, J; Lobo, C; Lopes, G; Morgenzstern, D; Reis, I; Santos, E; Silva, O; Slingerland, J; Welsh, C | 1 |
| Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R | 1 |
| Bar-Sela, G; Haim, N | 1 |
| Hampton, T | 1 |
| Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L | 1 |
| Baum, MS; Goldsmith, YB; Roistacher, N | 1 |
| Paoletti, P | 1 |
| Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M | 1 |
| Harada, T; Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N | 1 |
| Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y | 1 |
| Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Bagnardi, V; Bertolini, F; Campagnoli, E; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Mancuso, P; Pietri, E; Rocca, A; Scarano, E; Shaked, Y; Torrisi, R | 1 |
| Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A | 1 |
| Kamei, T; Kaneda, Y; Kurata, S; Miyamoto, S; Nakayasu, K; Suto, R; Zenpo, N | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osaki, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Cianfrocca, M | 1 |
| Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R | 1 |
| Glück, S; McKenna, EF; Royce, M | 1 |
| Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H | 1 |
| Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP; Salanti, G | 1 |
| Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J | 1 |
| Leonard, RC; Morishita, M | 1 |
| Yardley, DA | 1 |
| Albain, K; Barlow, WE; Chew, HK; Gown, A; Gralow, J; Hayes, DF; Hortobagyi, GN; Lew, D; Livingston, R | 1 |
| Fukushima, M; Ishida, T; Ishioka, C; Ishiwata, R; Kiba, T; Masuda, N; Matsuyama, K; Noguchi, S; Ohuchi, N; Takatsuka, Y; Takeda, M; Teramukai, S | 1 |
| Hay, JW; Le, QA | 1 |
| Frye, DK | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Amonkar, MM; Cameron, D; Cella, D; Geyer, CE; Segreti, A; Stein, S; Walker, M; Zhou, X | 1 |
| Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J | 1 |
| Boehnke Michaud, L | 1 |
| Shao, ZY; Zhang, JD | 1 |
| Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Brandely, M; Crivellari, D; Foa, P; Fougeray, R; Goldhirsch, A; Mattioli, R; Nolè, F; Pinotti, G; Verri, E | 1 |
| Chiba, A; Fukahori, M; Inaba, M; Inari, H; Ino, H; Yoshida, A | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| Aprile, G; Mazzer, M; Moroso, S; Puglisi, F | 1 |
| Greil, R; Menzel, C; Mlineritsch, B; Moik, M; Namberger, K; Reitsamer, R; Ressler, S; Stoll, M | 1 |
| Moore, S | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Andersson, M; Bauer, W; Baumann, KH; Clemens, MR; Cufer, T; de Jongh, FE; du Bois, A; Duerr, R; Kaufmann, M; Loibl, S; Maartense, E; Maass, N; Nekljudova, V; Schmidt, M; Stein, RC; Uleer, C; von Minckwitz, G; Zielinski, C | 1 |
| Burstein, HJ; Gelman, RS; Harris, LN; Mayer, EL; Partridge, AH; Schumer, ST; Winer, EP | 1 |
| Imai, S; Kobayashi, A; Koyama, H; Matsuyama, T; Tokugawa, T | 1 |
| Ghosal, N; Misra, V | 1 |
| Darodes, N; Genet, D; Labourey, JL; Le Brun-Ly, V; Martin, J; Tubiana-Mathieu, N; Venat-Bouvet, L | 1 |
| Filip, S; Finek, J; Holubec, L; Kormunda, S; Kozevnikova, R; Pavlikova, I; Sediva, M; Sefrhansova, L; Svoboda, T; Votavova, M | 1 |
| Hillner, BE; Smith, TJ | 1 |
| Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA | 1 |
| Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Becze, E | 1 |
| Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC | 1 |
| Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH | 1 |
| Inaba, T; Kashiwaba, M; Komatsu, H; Takeda, Y; Takiyama, I; Tomisawa, Y; Wakabayashi, G | 1 |
| Fujii, T; Inoue, Y; Matsubayashi, RN; Momosaki, S; Sawada, Y; Shirouzu, K; Takahashi, H; Toh, U; Uesugi, N; Yokoyama, G | 1 |
| Chan, A; Verrill, M | 1 |
| Alonso, V; Calduch, L; Jordá, E; Martín, JM; Pinazo, MI; Villalón, G | 1 |
| Grimison, PS; Hudson, HM; Simes, RJ; Stockler, MR | 1 |
| Eskola, M; Ilveskoski, E; Nikus, K; Tanner, M | 1 |
| Falleti, J; Fortuna, G; Leuci, S; Mignogna, MD | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Balducci, M; D'Agostino, GR; Dinapoli, N; Mantini, G; Massaccesi, M; Mattiucci, GC; Meduri, B; Micciché, F; Nardone, L; Salvi, G; Valentini, V | 1 |
| Alfonso, PG; Cañón, EP; Carrión, JB; Manga, GP; Pereira, RQ; Peron, YI; Plaza, MI; Shahi, PK; Ureña, MM; Val, RG | 1 |
| Becquart, D; Bougnoux, P; Chan, A; Conte, PF; Espie, M; Majois, F; Morand, M; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G | 1 |
| Chow, LW; Hirakawa, H; Ishida, T; Loo, WT; Ohuchi, N; Ono, K; Sasano, H; Suzuki, T | 1 |
| Giannopoulos, A; Gogas, H; Markopoulos, C; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N | 1 |
| Jordá, E; López, V; Martín, JM | 1 |
| Ang, BW; Cheng, CL; Chou, N; Lee, KM; Lee, SC; Wong, AL | 1 |
| Cathomas, R; von Moos, R | 1 |
| Barrett-Lee, P; Bidard, FC; Pierga, JY | 1 |
| Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N | 1 |
| Moen, MD | 1 |
| Albain, KS; Bedard, PL; Cardoso, F; Costa, A; Cufer, T; Fallowfield, LJ; Kyriakides, S; Pagani, O; Senkus-Konefka, E; Winer, EP | 1 |
| Jones, A; Nowara, E; O'Brien, M; Perraud, K; Pham, ML; Pienkowski, T; Rolski, J; Sommer, H; Trillet-Lenoir, V; Welt, A | 1 |
| Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J | 1 |
| Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Jassem, J; Li, RK; Mukhopadyay, P; Pivot, XB; Roché, HH; Thomas, ES | 1 |
| Górnaś, M; Szczylik, C | 1 |
| Amadori, D; Aquilina, M; Cecconetto, L; Ibrahim, T; Maltoni, R; Massa, I; Nanni, O; Passardi, A; Pietri, E; Ridolfi, R; Rocca, A; Sarti, S | 1 |
| Mortimer, J; Pal, SK | 1 |
| Brearley, SG; Craven, O; Molassiotis, A; Saunders, M; Swindell, R | 1 |
| Zeng, YC | 1 |
| Altundag, K; Dede, DS; Dizdar, O | 1 |
| Anderson, RT; Balkrishnan, R; Camacho, FT; Kimmick, G; Wei, W; Wu, J | 1 |
| Hasegawa, N; Iimura, Y; Kaneko, H; Kawabata, M; Konishi, K; Shoji, Y | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Lee, SJ; Min, SY; Nam, BH; Park, C; Park, IH; Ro, J; Shin, KH | 1 |
| Jager, A; Sleijfer, S; Verweij, J | 1 |
| Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N | 1 |
| Frampton, JE | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R | 1 |
| Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C | 1 |
| Hayashida, T; Ikeda, T; Jinno, H; Kitagawa, Y; Mukai, M; Sakata, M; Takahashi, M | 1 |
| Puglisi, F | 1 |
| Aboagye, EO; Al-Nahhas, A; Contractor, KB; Coombes, RC; Kenny, LM; Palmieri, C; Shousha, S; Stebbing, J | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| Amari, M; Ishida, T; Ohuchi, N; Takeda, M | 1 |
| Gohler, T; Hesse, T; Nusch, A; Siedentopf, F; Sulberg, H | 1 |
| Guarneri, V | 1 |
| Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Hemminki, A; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Lahtela, SL; Lehtiö, K; Leinonen, M; Lindman, H; Nilsson, G; Nuortio, L; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N | 1 |
| Brearley, S; Craven, O; Farrell, C; Luker, K; Molassiotis, A; Saunders, M; Swindell, R; Todd, C; Wardley, A | 1 |
| Schwartz, J | 1 |
| Castaneda, CA; Gómez, HL | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Brouste, V; Debled, M; Donamaria, C; Durand, M; Floquet, A; Madranges, N; Mauriac, L; Trainaud, A | 1 |
| Camphausen, K; Hunter, K; Korde, LA; Lebowitz, PF; Lukes, L; Lusa, L; McShane, L; Parker, JS; Swain, SM; Zujewski, JA | 1 |
| Goodin, S; Toppmeyer, DL | 1 |
| Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM | 1 |
| Kohles, J; Rugo, HS; Schulman, KL | 1 |
| Georgoulias, V; Mauri, D; Mavroudis, D; Patsopoulos, NA; Polyzos, NP; Valachis, A | 1 |
| Pikó, B | 1 |
| Anan, K; Masuda, N; Mitsuyama, S; Nishimura, R; Ohno, S; Takamatsu, Y; Tamura, K; Tanaka, M; Yamamoto, Y | 1 |
| Nakayama, T; Noguchi, S | 1 |
| Crivellari, D; Lestuzzi, C; Meneguzzo, N; Rigo, F; Viel, E | 1 |
| Stein, A | 1 |
| Jia, W; Li, J; Li, L; Sun, T; Tian, J; Yang, K; Yi, K; Zhang, P | 1 |
| Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E | 1 |
| Chiuri, V; Ciccarese, M; Cinieri, S; Colucci, G; Gasparini, G; Giampaglia, M; Lorusso, V; Manca, C; Silvestris, N; Tinelli, A | 1 |
| Ferraz, MB; Puga, ME; Riera, R; Soárez, PC | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Macková, D | 1 |
| Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA | 1 |
| Naughton, M | 1 |
| Bauerfeind, I; Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kühn, T; Loibl, S; Mehta, K; Rezai, M; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 2 |
| Gralow, J; Martin, M; Zielinski, C | 1 |
| Aogi, K; Barrios, CH; Brickman, MJ; Ferrero, JM; Harbeck, N; Iwata, H; Kern, KA; Lee, SC; Liu, MC; Lugo-Quintana, R; Martin, M; Pivot, X; Tabei, T; Vanlemmens, L; Zhang, K | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Abadie-Lacourtoisie, S; Brain, E; Esterni, B; Fargeot, P; Geneve, J; Joly, F; Laguerre, B; Luporsi, E; Retornaz, F; Rousseau, F; Servent, V | 1 |
| Archer, L; Berry, D; Gralow, J; Grenier, D; Hudis, C; Kastrissios, H; Kornblith, AB; Muss, H; Partridge, AH; Perez, E; Wang, X; Winer, E; Wolff, AC | 1 |
| Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE | 1 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y | 1 |
| Kawaguchisakita, N; Kohno, Y; Tsubota, Y; Tsuyuki, S; Ukikusa, M | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T | 1 |
| Emiliani, A; Losanno, T; Manna, G; Seminara, P | 1 |
| Brauchli, P; Dedes, KJ; Matter-Walstra, KW; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD | 1 |
| Chan, VF; Chung, HC; Fein, LE; Gomez, HL; Hortobagyi, GN; Hurtado de Mendoza, F; Jassem, J; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Vahdat, LT; Xu, B | 1 |
| Fan, Y; Wang, J; Xu, B | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Hudis, C; Norton, L; Traina, T | 1 |
| Cristofanilli, M | 1 |
| Buchholz, TA; Debeb, BG; Woodward, WA; Xu, W | 1 |
| Dugan, U; Higgins, B; Hudis, CA; Kolinsky, K; Norton, L; Theodoulou, M; Traina, TA | 1 |
| Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B | 1 |
| Pownall, M | 1 |
| Bozzarelli, S; Carnaghi, C; Colombo, P; De Vincenzo, F; Giorgetti, PL; Rimassa, L; Santoro, A; Sclafani, F | 1 |
| Braun, M; Jaehde, U; Ko, YD; Kuhn, W; Mey, UJ; Ringsdorf, S; Schmidt-Wolf, I; Schwindt, PF; Simons, S | 1 |
| Chauvin, F; Guastalla, JP; Jacquin, JP; Nourissat, A; Poirson, J; Regnier Denois, V | 1 |
| Anton, A; Bermejo, B; Casado, A; Gayo, J; Lao, J; Lluch, A; Martin, M; Muñoz, M; Paules, AB; Provencio, M | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Belau, A; Darb-Esfahani, S; Denkert, C; Hauschild, M; Högel, B; Huober, J; Khandan, F; Loibl, S; Mehta, K; Tesch, H; Thomssen, C; von Minckwitz, G; Weiss, E; Zahm, DM | 1 |
| Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT | 1 |
| Amant, F; Christiaens, MR; Debrock, G; Neven, P; Paridaens, R; Renard, V; Smeets, A; Squifflet, P; Van Eenoo, L; van Limbergen, E; Weltens, C; Wildiers, H; Wynendaele, W | 1 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I | 1 |
| Cameron, D; Casey, M; Geyer, CE; Imwalle, B; Newstat, B; Oliva, C | 1 |
| Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W | 1 |
| Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J | 1 |
| Hu, W; Li, L; Sheng, Y; Shi, J; Su, D; Wang, CK | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Baas, J; Bloemendal, HJ; Boven, E; de Graaf, H; Hop, WC; Kroep, JR; Linn, SC; Mandjes, IA; Nortier, JW; Schröder, CP; Smit, WM; van den Bosch, J; Vermeulen, GJ | 1 |
| Egerton, N | 1 |
| Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N | 1 |
| Fornier, M | 1 |
| Jeong, JH; Jung, SY; Kang, HS; Kim, EA; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J | 1 |
| Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H | 1 |
| Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH | 1 |
| Blum, JL; Glück, S; Hu, S; Kaye, JA; Kohles, J; McKenna, E; Odom, D; Scotto, N | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Aftimos, P; Chahine, G; Farhat, FS; Ghosn, M; Haddad, N; Hanna, C; Kattan, JG; Nasr, F | 1 |
| Hassan, M; Osman, MM | 1 |
| Inoue, H; Murakami, M; Nishizaki, T; Shimabukuro, R; Shiraishi, T; Takahashi, I; Yano, H | 1 |
| Hao, XS; Hou, Y; Li, LF; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Xie, CH; Zhang, HL; Zhou, SY | 1 |
| Ahn, JS; Cho, EY; Choi, YL; Im, YH; Kim, ST; Lee, SJ; Park, YH | 1 |
| Bachelot, T; Biron, P; Blay, JY; Favier, B; Galy, G; Guastalla, JP; Labidi-Galy, SI; Latour, JF; Perol, D; Ray-Coquard, I; Tredan, O | 1 |
| Baumann, I; Darb-Esfahani, S; Denkert, C; Grasshoff, ST; Heinrich, G; Hoffmann, G; Kronenwett, R; Loibl, S; Müller, BM; Noske, A; Roller, M; Steffen, J; Ulmer, HU; von Minckwitz, G; von Toerne, C; Wirtz, R | 1 |
| Chen, D; Chen, DS; Cobleigh, MA; Harris, AL; Hillan, KJ; Jubb, AM; Koeppen, H; Langmuir, VK; Miller, KD; Reimann, JD; Rugo, HS; Schmidt, M | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Boban, M; Boskovic, L; Fridl-Vidas, V; Hrepic, D; Omrcen, T; Vrdoljak, E | 1 |
| Guan, X; Guo, J; He, Z; Li, F; Mao, W; Tucker, S; Wang, J; Wu, S | 1 |
| Archer, L; Bennett, S; Casey, R; Cohen, HJ; Hudis, C; Kimmick, G; Kornblith, AB; Lan, L; Muss, HB; Partridge, A; Winer, E | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J | 1 |
| Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C | 1 |
| Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L | 1 |
| Feigin, K; Gajria, D; Geneus, S; Hudis, CA; Norton, L; Patil, S; Tan, LK; Theodoulou, M; Traina, TA | 1 |
| Ezaki, T; Iguchi, T; Kono, M; Maeda, T; Matsukuma, A; Mori, E; Nozoe, T | 1 |
| Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW | 1 |
| Ashley, S; Dolly, S; Johnston, S; Kotsori, AA; Parton, M; Shaunak, N; Sheri, A; Smith, IE; Walsh, G | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Conn, CE; Danon, SJ; Drummond, CJ; Gong, X; Moghaddam, MJ; Sagnella, SM; Waddington, LJ | 1 |
| Bruno, R; Claret, L; Frances, N; Iliadis, A | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P | 1 |
| Morita, S | 1 |
| Arakawa, A; Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Orihata, G; Ozawa, S; Saito, M; Sasai, K | 1 |
| Chi, HD; Chua, D; Jiang, ZF; Liu, DG; Luo, RC; Martin, AM; Newstat, B; Preston, A; Shao, ZM; Wang, L; Wang, XJ; Xu, BH; Yeo, W; Yu, SY | 1 |
| Adua, D; Basile, ML; De Sanctis, R; Del Signore, E; Di Seri, M; Gori, B; Grassi, P; Longo, F; Quadrini, S; Stumbo, L | 1 |
| Borštnar, S; Cwiertka, K; Das Gupta, A; Greil, R; Koza, I; Linn, M; Marcou, Y; Petráková, K; Pikiel, J; Steger, GG; Wojtukiewicz, MZ | 1 |
| Alvarez, RH; Hortobagyi, GN; Valero, V | 1 |
| Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L | 1 |
| Bell, JA; Conte, P; Corey-Lisle, PK; Hortobagyi, G; Mukhopadhyay, P; Orsini, L; Peck, R; Revicki, DA; Roche, H; Safikhani, S | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R | 1 |
| Baghel, NS; Basu, S | 1 |
| Damante, G; Di Loreto, C; Pandolfi, M; Puglisi, F; Puppin, C | 1 |
| Donders, AR; Oostendorp, LJ; Ottevanger, PB; Stalmeier, PF; van der Graaf, WT | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Buzdar, AU; Cheporov, S; Digumarti, R; Goedhals, L; Gotovkin, E; Hoersch, S; Hu, X; Miles, DW; O'Shaughnessy, J; Rittweger, K; Semiglazov, V; Tjulandin, S; Xu, B | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Guo, H; Hu, X; Jia, Z; Shao, Z; Sun, S; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N | 1 |
| Amonkar, MM; Browning, D; Cameron, D; Delea, TE; Karnon, J; Sofrygin, O; Tappenden, P; Walker, MD | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Andersson, M; Barinoff, J; Baumann, KH; Bischoff, J; Cufer, T; de Jongh, FE; Harbeck, N; Loibl, S; Lück, HJ; Maartense, E; Maass, N; Mundhenke, C; Nekljudova, V; Schmidt, M; Schwedler, K; Stein, RC; von Minckwitz, G; Zielinski, C | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J | 1 |
| Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N | 1 |
| Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z | 1 |
| Chen, C; D'Andrea, G; Drullinsky, P; Feigin, K; Gajria, D; Gonzalez, J; Hudis, CA; Lake, D; Norton, L; Patil, S; Theodoulou, M; Traina, TA | 1 |
| de Los Ríos la Rosa, F; Privitera, M | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z | 1 |
| Campone, M; Fein, L; Jassem, J; Karwal, M; Peck, R; Poulart, V; Vahdat, L | 1 |
| Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Ackland, SP; Byrne, MJ; Coates, AS; Fitzharris, B; Fong, A; Forbes, JF; Francis, PA; Gainford, MC; Gebski, V; Grimison, PS; Harvey, VJ; Nowak, AK; Paksec, L; Simes, RJ; Sourjina, T; Stockler, MR; Van Hazel, G; Wilcken, NR; Zannino, D | 1 |
| Croom, KF; Dhillon, S | 1 |
| Bonneterre, J; Bourbouloux, E; Campone, M; Fumoleau, P; Isambert, N; Milano, G; Roché, H | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| van Tienhoven, G; Wilmink, JW | 1 |
| Colucci, G; D'Amico, C; Di Lauro, L; Giannarelli, D; Giotta, F; Latorre, A; Mariani, L; Pizzuti, L; Sergi, D; Vici, P; Vizza, E | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Earl, HM | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Arena, FP; Epperson, AL; Mintzer, DM; Schwartzberg, LS; Walker, MS | 1 |
| Amatu, A; Bernardo, A; Bernardo, G; Frascaroli, M; Montagna, B; Palumbo, R; Poggi, G; Riccardi, A; Sottotetti, F; Strada, MR; Tagliaferri, B; Teragni, C | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ | 1 |
| Kishi, S; Matsumoto, A; Morise, M; Suzuki, H; Suzuki, T; Takeshita, T; Tsutsui, A; Yoneyama, K | 1 |
| Ishiba, T; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C | 1 |
| Albain, KS; Barlow, WE; Chew, HK; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lanier, KS; Lew, DL; Livingston, RB; Schott, AF; Wade, JL | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Bhattacharya, D; Easthall, C; Small, M; Watson, S; Willoughby, KA | 1 |
| Beath, KJ; Bulger, D; Gebski, V; Heller, GZ; Kifley, A; Ma, J | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T | 1 |
| Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Luini, A; Mancuso, P; Montagna, E; Pastrello, D; Sandri, MT | 1 |
| O'Shaughnessy, JA; Perez, EA; Rugo, HS | 2 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Han, HS; Jung, S; Kang, HS; Kim, SW; Lee, H; Lee, KS; Lee, S; Park, IH; Ro, J | 1 |
| Du, Y; Jiang, Y; Lu, J; Shao, Z; Shen, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q | 1 |
| Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
| Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F | 1 |
| Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B | 1 |
| Allred, JB; Bernath, AM; Fishkin, PA; Fitch, TR; Flynn, P; Perez, EA; Salim, M; Stella, PJ; Tan, WW; Wiesenfeld, M | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S | 1 |
| Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Abe, C; Furusawa, H; Hirata, M; Kawaguchi, Y; Morita, S; Okamoto, Y; Sakamoto, J; Takami, M; Takao, S; Yamashita, S; Yoshimoto, M | 1 |
| Ishikawa, T; Tukamoto, Y; Yasaki, S; Yoshii, F; Yuasa, N | 1 |
| Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T | 1 |
| Gradishar, WJ | 2 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| Bosserman, L; Gómez, H; Li, RK; Manikhas, A; Medina, C; Mukhopadhyay, P; Opatt, D; Ro, J; Sparano, JA; Thomas, E; Vahdat, L; Valero, V; Vrdoljak, E; Xu, B | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Bergenfeldt, M; Hermann, KL; Jensen, BK; Jensen, BV; Nelausen, KM; Nielsen, DL; Nørgaard, H; Pfeiffer, P; Vestermark, LW | 1 |
| Azuma, Y; Fujiwara, Y; Hata, K; Hirakawa, A; Makino, Y; Morikawa, N; Ryushima, Y; Sai, K; Saito, Y; Tohkin, M; Udagawa, R; Yamamoto, H; Yokote, N | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| Archer, LE; Cohen, HJ; Hudis, CA; Muss, HB; Partridge, AH; Pitcher, BN; Ruddy, KJ; Winer, EP | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B | 1 |
| Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J | 1 |
| Carrié, S; Cottu, P; De Rycke, Y; Falcou, MC; Llambrich, C; Medjbari, M | 1 |
| Lim, E; Lin, NU | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Inaba, S; Koyama, H; Nakatsukasa, K; Tokugawa, T | 1 |
| Guillen, C; Kindem, S; Llombart, B; Requena, C; Ruiz, A; San Martin, O; Traves, V | 1 |
| Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G | 1 |
| Frances, N; Iliadis, A; Marouani, H; Mercier, C; Woloch, C | 1 |
| Gligorov, J; Joensuu, H | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M | 1 |
| Gan, Y; Gu, SY; Guo, HY; Hu, XC; Wang, BY; Wang, JL; Wang, LP; Wang, ZH; Zhang, J; Zhao, XM | 1 |
| Delozier, T; Ettl, J; Finek, J; Glogowska, I; Kilar, E; Malamos, N; Palomo, AG; Sommer, H; Torrecillas, L; Vega, JM | 1 |
| Chachad, S; Malhotra, G; Naidu, R; Purandare, S | 1 |
| Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY | 1 |
| Barrios, CH; Blum, JL; Feldman, N; Gralow, J; Lee, LF; McKenna, EF; Scotto, N; Verma, S | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Bartsch, R; Preusser, M | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Meng, L; Wang, Y; Wei, JF; Yang, H | 1 |
| Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| de Ronde, JJ; Kerkhoven, R; Lips, EH; Mulder, L; Nieuwland, M; Rodenhuis, S; Sonke, GS; Vincent, AD; Vrancken Peeters, MJ; Wesseling, J; Wessels, LF | 1 |
| Benekli, M; Berk, V; Boruban, C; Buyukberber, S; Cetin, B; Coskun, U; Dane, F; Harputluoglu, H; Isıkdogan, A; Kaplan, MA; Koca, D; Koral, L; Oksuzoglu, B; Sevinc, A; Turker, I; Ulas, A; Uncu, D; Yilmaz, B | 1 |
| Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M | 1 |
| Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW | 1 |
| Bonotto, M; Bozza, C; Di Loreto, C; Osa, EO; Poletto, E; Puglisi, F | 1 |
| Champeny, TL; Chang, JE; Hansen, RM; Kim, K; Meadows, S; Njiaju, UO; Powers, K; Stewart, JA; Tevaarwerk, AJ; Traynor, AM; Van Ummersen, L | 1 |
| Downs, E; Guron, G; Shaaban, H; Shakouri, P | 1 |
| Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q | 1 |
| Ishiba, T; Kasahara, M; Nagahara, M; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H; Tamura, N; Yamauchi, S | 1 |
| Amamori, K; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamagiwa, K; Yamanda, T | 1 |
| Nieder, C | 1 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H | 1 |
| D'Alessio, A; Daniele, G; De Luca, A; Del Giudice, A; Gallo, M; Giordano, P; La Porta, ML; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Gabram, SG; Harichand-Herdt, S; Kim, S; Liu, Y; O'Regan, RM; Rizzo, M; Styblo, TM; Wood, WC; Zelnak, AB | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Elghazaly, H; Rostom, Y; Tawfik, H | 1 |
| Kato, T; Okamura, R; Sata, R | 1 |
| Morimoto, M; Nakagawa, M; Tangoku, A | 1 |
| Miles, DW | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| O'Shaughnessy, JA | 2 |
| Bolognia, JL; Glusac, EJ; Willey, A | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Hudis, CA | 1 |
| O'Shaughnessy, J | 2 |
| Budman, DR | 2 |
| Livingston, R | 1 |
| Adjei, AA; Dy, GK | 1 |
| Liu, CY | 1 |
| Aapro, M; Seidman, AD | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Misset, JL; O'Shaughnessy, J; Seidman, AD | 1 |
| Biganzoli, L; Martin, M; Twelves, C | 1 |
| Brunner, M; Eichler, HG; Locker, G; Mader, RM; Mueller, M; Rizovski, B; Schrolnberger, C; Steger, GG; Wenzel, C | 2 |
| Goa, KL; Ibbotson, T; Wagstaff, AJ | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Gerbrecht, BM | 1 |
| Seidman, AD | 1 |
| Gradishar, WJ; Kaklamani, VG | 1 |
| Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P | 1 |
| Ilersich, AL; Verma, S | 1 |
| Mayor, S | 1 |
| Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Crucitta, E; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Misino, A; Silvestris, N | 1 |
| Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G | 1 |
| Brickell, K; Porter, D; Thompson, P | 1 |
| Jones, KL; Valero, V | 1 |
| Clippe, C; Freyer, G; Milano, G; Trillet-Lenoir, V | 1 |
| Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH | 1 |
| Blum, JL; Fumoleau, P; Reichardt, P | 1 |
| Maino, KL; Norwood, C; Stashower, ME | 1 |
| Nishida, M | 1 |
| Bar-Ziv, J; Siegelmann-Danieli, N; Stein, M | 1 |
| Giglio, P; Groves, MD; Tremont-Lukats, IW | 1 |
| Kornek, GV; Scheithauer, W; Schüll, B | 1 |
| Seidman, A | 1 |
| Remer, SE; Rogers, LR; Tejwani, S | 1 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E | 1 |
| Engin, H; Eren, OO; Güler, N; Kurt, M | 1 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Sakamoto, J; Toi, M | 1 |
| Miller, KD | 1 |
| Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K | 1 |
| Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Rugo, HS | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Herrmann, R; Niemann, B; Pless, M; Rochlitz, C | 1 |
| Baurain, JF; Duck, L; Henry, S; Machiels, JP | 1 |
| Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M | 1 |
| Ahn, JH; Ahn, SH; Kang, YK; Kim, SB; Kim, SM; Kim, TW; Kim, WK; Lee, JS; Park, JM | 1 |
| Jiang, ZF; Shen, G; Song, ST; Wang, T; Yu, JX; Zhang, SH | 1 |
| Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E | 1 |
| Holland, M; Reichardt, P; Sternberg, CN | 1 |
| Hoff, P; Lassere, Y | 1 |
| Deery, P; Faithfull, S | 1 |
| Gerbrecht, BM; Kangas, T | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, K; Lee, J; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Nam, E; Park, J; Park, JO; Park, K; Park, SH; Park, YS; Yoon, SS | 1 |
| Blum, J; Scheithauer, W | 1 |
| Leonard, R; Miles, D; Reichardt, P; Twelves, C | 1 |
| Cameron, D; Fumoleau, P | 1 |
| Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J | 1 |
| Ayoub, JP; Cervantes, G; Liu, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, JA; Van Hazel, G; Vukelja, S | 1 |
| Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS | 1 |
| Aebi, S; Ballabeni, P; Brauchli, P; Mingrone, W; Pestalozzi, BC; Rauch, D; Rijken, N; Rochlitz, C; Uhlmann, C | 1 |
| Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B | 1 |
| Saeki, T; Takashima, S | 2 |
| Barats, JC; Baticle, JL; Brewer, Y; Chollet, P; Fumoleau, P; Gil-Delgado, M; Goudier, MJ; Martin, D; Namer, M; Pierga, JY; Sutherland, W; Turpin, FL; Zelek, L | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Gerber, B; Heinrich, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Löhr, A; Raab, G; von Minckwitz, G; Zuna, I | 1 |
| Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Chap, LI; Cobleigh, MA; Dickler, M; Fehrenbacher, L; Holmes, FA; Langmuir, V; Marcom, PK; Miller, KD; Overmoyer, BA; Reimann, JD; Rugo, HS; Sing, AP | 1 |
| Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N | 1 |
| Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Hornberger, J; Jamieson, C; Jones, S; Maraninchi, D; Martín, M; McKendrick, J; Miles, D; O'Shaughnessy, J; Twelves, C; Verma, S | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Araki, K; Kobayashi, M; Moriki, T; Namikawa, T; Okabayashi, T; Okamoto, K; Sugimoto, T; Tochika, N | 1 |
| Kahlert, S; Konecny, G; Rueckert, S; Ruehl, I; Untch, M | 1 |
| Coutsouvelis, J; McKendrick, J | 1 |
| Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Longhi, S; Munzone, E; Nolè, F; Pagani, O; Ruggeri, M; Sessa, C; Thürlimann, B | 1 |
| Blum, JL; Clark, RS; Liepa, AM; Melemed, AS; Mennel, RG; O'Shaughnessy, JA; Snyder, D; Yardley, DA; Ye, Z | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Hikino, H; Johbara, K; Obayashi, N; Ozaki, N; Yamada, T | 1 |
| Cheng, CW; Ching Chan, S; Chow, LW; Ngor Wong, L; Tong, DK | 1 |
| Haim, N; Isaacs, K | 1 |
| Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N | 1 |
| Anan, K; Mitsuyama, S; Ono, M | 1 |
| Clemons, M; Dranitsaris, G; Joy, AA; MacKey, JR; Trudeau, M; Verma, S | 1 |
| Erkisi, M; Kara, IO; Sahin, B | 1 |
| Le Pen, C; Maurel, F; Priol, G | 1 |
| Coleman, RE; El-Helw, L | 1 |
| Baddi, L; Beck, AC; Blumenthal, DT; Chua-Adajar, R; Futterer, S; Gradishar, W; Raizer, JJ; Semenov, I; Simuni, T; Tellez, C; Videnovic, A | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| Baker, LH; Griffith, KA; Hayes, DF; Rae, JM; Schott, AF; Sterns, V | 1 |
| Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P | 1 |
| Adamoli, L; Blanchot, G; Catania, C; Goldhirsch, A; Imadalou, K; Longerey, B; Munzone, E; Nolè, F; Sanna, G | 1 |
| Alabiso, O; Ardine, M; Beano, A; Berruti, A; Bertetto, O; Bonardi, S; Bottini, A; Bretti, S; Castiglione, F; Donadio, M; Generali, D; Mistrangelo, M; Polimeni, MA | 1 |
| Ebi, H; Minami, H | 1 |
| Marutaka, M; Miyake, M; Suguri, T; Yoshimura, K | 1 |
| Fumoleau, P; Levy, C | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Ershler, WB | 2 |
| Asproudis, I; Gorezis, S; Peschos, D; Psilas, K; Stefaniotou, M | 1 |
| Akcali, Z; Basturk, B; Ozyilkan, O; Yildirim, Y | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Muss, HB; Perez, E | 1 |
| Kimura, T; Saeki, T; Taguchi, T; Toi, M | 1 |
| Cardinale, D; Colombo, A; Colombo, N | 1 |
| Adamoli, L; Ascione, G; Catania, C; Goldhirsch, A; Minchella, I; Munzone, E; Nolè, F; Rocca, A; Sanna, G; Verri, E; Zampino, MG | 1 |
| Abraham, J; Higa, GM; Kovach, RF | 1 |
| Chew, HK; Gandara, D; Juhasz, A; Vassilakos, A; Yen, Y | 1 |
| Bernhard, H; Harbeck, N; Heinemann, V; Lässig, D; Schmitt, M; Schoenberg, S; Stemmler, HJ; Willems, A | 1 |
| Barone, C; Cassano, A; Crea, F; Lanza, GA; Pozzo, C; Sestito, A; Sgueglia, GA | 1 |
| Cao, D; Pizzorno, G; Wan, L; Yan, R | 1 |
| Carrato Mena, A; Gallego Plazas, J; Maciá Escalante, S; Martínez Banaclocha, N; Rodríguez Lescure, A | 1 |
| Calabrese, R; Colucci, G; Giampaglia, M; Guida, M; Latorre, A; Lorusso, V; Misino, A; Monticelli, G; Sambiasi, D; Spada, M | 1 |
| Blum, JL; O'Shaughnessy, JA | 1 |
| Ito, Y; Tokudome, N | 1 |
| Smith, IE | 1 |
| Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D | 1 |
| Elledge, R; Hinckley, L; Teh, BS; Tham, YL | 1 |
| Aksoy, S; Guler, N; Kurt, M | 1 |
| Hague, JS; Ilchyshyn, A | 1 |
| Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC | 1 |
| Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G | 1 |
| Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Chacko, A; Dees, EC; Doane, L; Ethirajan, S; Hopkins, J; Ilegbodu, D; McMahon, R; Merten, S; Negron, A; Neubauer, M; O'Shaughnessy, JA | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| Wardley, A | 1 |
| Jackisch, C | 1 |
| Chan, A; Gelmon, K; Harbeck, N | 1 |
| Carmona-Bayonas, A | 1 |
| Ciccolini, J; Etienne-Grimaldi, MC; Ferrero, JM; Foa, C; Formento, JL; Francoual, M; Ginot, A; Lacarelle, B; Largillier, R; Milano, G; Namer, M; Nebbia, JF; Renée, N | 1 |
| Bashir, T; Budman, DR; Mandelblat, J | 1 |
| Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K | 1 |
| Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L | 1 |
| Ockenfels, HM; Saborowski, A; Sauter, C | 1 |
| Bosch, RJ; Herrera, E; López, N; Tejera, A | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Bouriel, C; Bridji, B; Campion, L; Campone, M; Chatal, JF; Clouet, M; Delecroix, V; Devillers, A; Doutriaux, I; Ferrer, L; Garin, E; Kerbrat, P; Resche, I; Ricaud, M; Rouquette, S; Rousseau, C; Sagan, C | 1 |
| Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S | 1 |
| Muss, HB | 1 |
| Honma, H | 1 |
| Joensuu, H; Kellokumpu-Lehtinen, PL; Lehtinen, I; Sjöström-Mattson, J; Sunela, K | 1 |
| Doyle, DP; Engelking, C | 1 |
| Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C | 1 |
| Amorim, G; Arcuri, RA; Biasoli, I; Djahjah, C; Gaui, MF; Moreira, D; Pereira, G; Spector, N | 1 |
| Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C | 1 |
| Akahane, T; Chiba, T; Hashimoto, Y; Yano, H | 1 |
| Banerji, U; Johnston, SR; Kendall, A; O'Brien, M; Smith, IE; Walsh, G; Yap, YS | 1 |
| Amare, M; Asmar, L; Blum, JL; Dees, EC; Gill, DP; Ilegbodu, D; McMahon, RT; O'Shaughnessy, JA; Vukelja, SJ | 1 |
| Ahlgren, J; Bergh, J; Bergström, D; Blomqvist, C; Lidbrink, E; Lindh, B; Malmberg, L; Nordgren, H; Ohd, JF; Villman, K | 1 |
| Sonpavde, G | 1 |
| Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM | 1 |
| Baydal, R; Blanes, MD; Chirivella, I; Colio, JM; De-la-Morena, E; Laforga, J; Lluch, A; Perez-Fidalgo, JA; Roselló, S | 1 |
| Tripathy, D | 1 |
| Díaz-Rubio, E; García-Saénz, JA; Martín, M | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D | 1 |
| Clemons, M; Dranitsaris, G; Joy, A; Mackey, J; Trudeau, M; Verma, S; Wong, NS | 1 |
| Bangemann, N; Fuchs, I; Gonsch, T; Hindenburg, HJ; Hinke, A; Klare, P; Kleine-Tebbe, A; Lakner, V; Schaller, G; Weber, J | 1 |
| Bosserman, L; Cai, C; Hortobagyi, GN; Lerzo, G; Mullaney, B; Peck, R; Perez, EA; Pivot, X; Thomas, E; Vahdat, L; Viens, P | 1 |
| Abrey, LE; Deangelis, LM; Ekenel, M; Hormigo, AM; Peak, S | 1 |
| Diehl, KM; Griffith, KA; Hayes, DF; Hayman, JA; Helvie, MA; Layman, RM; Newman, LA; Pierce, LJ; Roubidoux, MA; Sabel, MS; Schott, AF; Smerage, JB; Thomas, DG | 1 |
| Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N | 1 |
| Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K | 1 |
| Fujino, M; Maruhashi, K; Mitsudou, Y; Nakamura, T; Shimomatsuya, T; Shiraishi, S; Yonezawa, K | 1 |
| Murakami, S; Yamamoto, Y | 1 |
| Kurebayashi, J; Masuda, N; Nakayama, T; Noguchi, S; Sakamoto, J; Shiba, E; Taguchi, T; Takatsuka, Y; Watatani, M | 1 |
| Chung, KW; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Kwon, HS; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Galán-Gutiérrez, M; Jiménez-Puya, R; Moreno-Giménez, JC; Rodríguez-Bujaldón, AL; Vázquez-Bayo, C | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Cameron, D | 1 |
| Kimura, Y; Morohashi, H; Morohashi, S; Odagiri, H; Sasaki, M | 1 |
| Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S | 1 |
| Barrett-Lee, P; Bliss, JM; Cameron, D; Canney, P; Johnson, L | 1 |
| Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osako, T; Takahashi, S; Tokudome, N | 1 |
| Chow, LW; Loo, WT; Sasano, H | 2 |
| Abeshima, S; Hasegawa, N; Ichimura, T; Kaneko, H; Kawabata, M; Konishi, K; Nakayama, T | 1 |
| Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T | 1 |
| Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B | 1 |
| Basaran, G; Blot, E; Bogaerts, J; Cameron, D; Canney, P; Coleman, R; Cufer, T; Ellis, P; Marreaud, S; Pajk, B; Piccart, M; Vermorken, J | 1 |
| Bell, R; Nortier, JW; Paridaens, R; Rodrigues, H; Rossner, D; Salzberg, M; Vaslamatzis, MM; Venturini, M | 1 |
| Thompson, CA | 1 |
| Gibson, DE; Szetela, AB | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S | 1 |
| Alomar, A; Dalmau, J; Puig, L; Roé, E | 1 |
| Collingridge, D | 1 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Saji, S; Sakamoto, J; Toi, M | 1 |
| Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P | 1 |
| Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Diasio, RB; Ledbetter, L; Saif, MW; Tomita, M | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D | 1 |
| Asselah, J; Cottu, PH; Diéras, V; Lae, M; Mignot, L; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A | 1 |
| Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H | 1 |
| Autret-Leca, E; Blasco, H; Boisdron-Celle, M; Bougnoux, P; Calais, G; Ciccolini, J; Le Guellec, C; Tournamille, JF | 1 |
| James, WD; Krathen, M; Treat, J | 1 |
| Bando, Y; Hirose, T; Honda, J; Moriya, T; Nagao, T; Sasa, M; Takahashi, M; Tangoku, A | 1 |
| Hachisuka, Y; Hatano, H; Johira, H; Kamei, Y; Kawata, N; Kimura, M; Miyata, N; Ohmori, K; Umeoka, T; Uomoto, M; Watanabe, R; Yunoki, S | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Vahdat, L | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G | 1 |
| Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA | 1 |
| Mukesh, M; Murray, P | 1 |
| Vahdat, LT | 1 |
| Burris, HA | 1 |
| Katirtzoglou, NA; Saif, MW; Syrigos, KN | 1 |
| Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Perez, EA | 1 |
| Thomas, ES | 1 |
| Krop, IE; Winer, EP | 1 |
| Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I | 1 |
| Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP | 1 |
| Bunnell, CA; Winer, EP | 1 |
| Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C | 1 |
| Timmerman, D | 1 |
| Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E | 1 |
| Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
| Cottu, PH; Cuvier, C; Espie, M; Lerebours, F; Marty, M | 1 |
| Blum, JL | 2 |
| Batchelder, KF | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Fraunfelder, FT; Henner, WD; Waikhom, B; Walkhom, B | 1 |
| Tanaka, C; Toi, M | 1 |
| Schilsky, RL | 1 |
| Awada, A; Piccart, MJ | 1 |
| Lewis, NL; Meropol, NJ | 1 |
| Mokbel, K | 1 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Moiseenko, VM; Orlova, RV; Semenova, AI | 1 |
| Leonard, RC | 1 |
| Blum, JL; Diab, S; Elledge, R; Griffin, T; Jones, SE; Khoury, P; Kraynak, M; Kromelis, P; Moczygemba, J; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, D | 1 |
| Collao Lamb, C; Popova, N; Sappino, AP; Schnetzler, B | 1 |
| Royce, ME; Schomer, DF; Theriault, RL; Wang, ML; Yung, WK | 1 |
| Chen, GY; Chen, WC; Chen, YH; Hsu, MM; Tsao, CJ | 1 |
| Gershanovich, ML; Semiglazova, TIu | 1 |
| Coleman, R; Cunningham, D | 1 |
| Twelves, C | 1 |
| Johnston, PG; Kaye, S | 1 |
| Bell, KA; Hsu, S; Perna, AG | 1 |
| Schwetz, BA | 1 |
| Leyland-Jones, B | 1 |
| Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R | 1 |
| Heinemann, V; Schmid-Wendtner, MH; Volkenandt, M; Wendtner, CM | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD | 1 |
| Ball, ED; Bashey, A; Corringham, S; Jones, V; Lancaster, D; Law, P; Silva-Gietzen, J; Sundaram, S | 1 |
| Diasio, RB | 1 |
| Bontenbal, M; Smorenburg, CH; Verweij, J | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Fujimoto-Ouchi, K; Sekiguchi, F; Tanaka, Y | 1 |
| Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J | 1 |
| Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Hwang, JJ; Marshall, JL | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Hohenberg, G; Ortmann, E | 1 |
186 review(s) available for capecitabine and Breast Neoplasms
| Article | Year |
|---|---|
Capecitabine induced fingerprint loss: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Receptor, ErbB-2 | 2022 |
Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Decision-Making; Disease Management; Female; Humans; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retreatment; Treatment Outcome | 2021 |
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Leukoencephalopathies; Triple Negative Breast Neoplasms | 2022 |
Metronomic Chemotherapy for Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Quality of Life; Receptor, ErbB-2 | 2022 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Systemic management of brain metastases in HER2+ breast cancer in 2022.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2022 |
Postneoadjuvant treatment for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Circulating Tumor DNA; Female; Humans; Neoadjuvant Therapy; Prognosis; Triple Negative Breast Neoplasms | 2022 |
Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Immunoconjugates; Lapatinib; Maytansine; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure | 2023 |
Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Recurrence, Local | 2023 |
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; In Situ Hybridization, Fluorescence; Prognosis; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2023 |
Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2023 |
Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Taxoids | 2023 |
A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Female; Fluorouracil; Humans; Progression-Free Survival | 2023 |
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Humans; Molecular Targeted Therapy; Network Meta-Analysis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2020 |
Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dermatoglyphics; Docetaxel; Female; Hand-Foot Syndrome; Humans | 2020 |
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Male; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms | 2020 |
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Humans; Middle Aged; Network Meta-Analysis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2020 |
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Humans; Quality of Life; Taxoids | 2020 |
Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review.
Topics: Breast Neoplasms; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Decision-Making; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Incidence; Keratosis, Actinic; Off-Label Use; Organ Transplantation; Patient Selection; Risk Assessment; Risk Factors; Skin Neoplasms; Transplant Recipients | 2020 |
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies; Triple Negative Breast Neoplasms | 2021 |
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Female; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2020 |
Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Female; Hand-Foot Syndrome; Humans; Middle Aged; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2020 |
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bias; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Quality of Life; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2021 |
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Treatment Outcome | 2021 |
Sorafenib for the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2017 |
Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Randomized Controlled Trials as Topic | 2017 |
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Triple Negative Breast Neoplasms | 2017 |
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Onychomadesis associated with chemotherapy: case report and mini literature review.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Follow-Up Studies; Humans; Nail Diseases; Paclitaxel | 2017 |
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Middle Aged; Mutation; Uridine | 2019 |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome | 2018 |
Breast cancer in 2017: Spurring science, marking progress, and influencing history.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2018 |
HER2-positive breast cancer: Current and new therapeutic strategies.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2018 |
Pyrotinib: First Global Approval.
Topics: Acrylamides; Aminoquinolines; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids | 2018 |
Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Neoplasm Grading; Progression-Free Survival; Taxoids; Treatment Outcome | 2018 |
Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Prognosis; Quality of Life; Receptor, ErbB-2; Remission Induction; Retrospective Studies | 2019 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2014 |
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Breast carcinoma with choriocarcinomatous features: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclobutanes; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Giant Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Organoplatinum Compounds; Prognosis; Retrospective Studies; Taxoids | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2015 |
HER2-positive metastatic breast cancer: a changing scenario.
Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Random Allocation; Stomatitis; Treatment Outcome | 2016 |
Vinflunine for the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Vinblastine | 2016 |
Systematic review of ixabepilone for treating metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Administration Schedule; Epothilones; Female; Furans; Humans; Ketones; Paclitaxel; Survival Analysis; Treatment Outcome | 2017 |
Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Female; Hand-Foot Syndrome; Humans | 2016 |
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Disease-Free Survival; Female; Humans; Neoplasm Staging; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate | 2016 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.
Topics: Administration, Metronomic; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Middle Aged; Seizures; Treatment Outcome | 2017 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Application of epothilones in breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Microtubules; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Tubulin Modulators | 2008 |
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Capecitabine and docetaxel combination for the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2008 |
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Tubulin Modulators | 2008 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Paresthesia; Patient Compliance; Patient Education as Topic; Peripheral Nervous System Diseases; Prodrugs | 2009 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neutropenia; Peripheral Nervous System Diseases; Premedication; Tubulin Modulators | 2009 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2009 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Nursing Assessment; Oncology Nursing; Pharmacogenetics; Risk Factors; Safety; Vomiting | 2009 |
Capecitabine and vinorelbine in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Practice Guidelines as Topic; Vinblastine; Vinorelbine | 2009 |
Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis | 2009 |
Ixabepilone: in locally advanced or metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Epothilones; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2009 |
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
Topics: Age Factors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Comorbidity; Congresses as Topic; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Europe; Evidence-Based Medicine; Female; Fluorouracil; Humans; International Cooperation; Karnofsky Performance Status; Menopause; Patient Selection; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Socioeconomic Factors; Taxoids; Vinblastine; Vinorelbine | 2009 |
Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Proportional Hazards Models; Risk Assessment; Risk Factors | 2009 |
Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Expression; Humans; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab | 2009 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Ixabepilone, a new treatment option for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epothilones; Female; Fluorouracil; Humans; Multicenter Studies as Topic | 2010 |
Interaction between capecitabine and brivudin in a patient with breast cancer.
Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Bromodeoxyuridine; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Onycholysis; Palliative Care; Peripheral Nervous System Diseases; Salvage Therapy; Stomatitis; Tooth Discoloration | 2010 |
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Japan; Methotrexate; Oxonic Acid; Tegafur; Uracil | 2010 |
Ixabepilone.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Epothilones; Female; Fluorouracil; Humans; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2010 |
Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Randomized Controlled Trials as Topic | 2010 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Evolution of capecitabine dosing in breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans | 2010 |
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Prodrugs; Treatment Outcome | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators | 2010 |
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Failure; Tubulin Modulators | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Ixabepilone for the treatment of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids | 2011 |
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Taxoids | 2011 |
Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Pseudomonas Infections; Superinfection | 2011 |
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Carcinoma; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
Adjuvant treatments for triple-negative breast cancers.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2012 |
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult | 2012 |
Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2012 |
Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Topics: Antimetabolites, Antineoplastic; Biomarkers; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prognosis; Thymidine Phosphorylase | 2013 |
[A case of metastatic breast cancer with bilateral hydronephrosis effectively treated with capecitabine].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Hydronephrosis; Middle Aged; Peritoneal Neoplasms | 2012 |
Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Models, Statistical; Neoadjuvant Therapy; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Risk Assessment; Taxoids; Treatment Outcome | 2013 |
Pharmacokinetic evaluation of capecitabine in breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs; Randomized Controlled Trials as Topic | 2013 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Delayed-Action Preparations; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
New directions with capecitabine combinations in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Humans | 2002 |
Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2002 |
Moving forward with capecitabine: a glimpse of the future.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Forecasting; Humans; Prodrugs; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Treatment Outcome | 2003 |
Current Canadian experience with capecitabine: partnering with patients to optimize therapy.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antimetabolites, Antineoplastic; Benchmarking; Breast Neoplasms; Canada; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Nurse's Role; Oncology Nursing; Safety; Treatment Outcome | 2003 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Role of capecitabine (Xeloda) in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Practice Guidelines as Topic | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2003 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy; Methotrexate; Neovascularization, Pathologic; Treatment Outcome | 2004 |
Bevacizumab in the treatment of breast cancer: rationale and current data.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Vascular Endothelial Growth Factor A | 2004 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nausea; Neutropenia; Nurse's Role; Oncology Nursing; Patient Education as Topic; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Fluorouracil; Gastrointestinal Neoplasms; Home Care Services; Humans; Nurse's Role; Oncology Nursing; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Decision Trees; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Foot; Hand; Humans; Nurse's Role; Nursing Assessment; Oncology Nursing; Paresthesia; Patient Education as Topic; Primary Prevention; Severity of Illness Index; Skin Care; Syndrome | 2004 |
Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Care Facilities; Capecitabine; Colorectal Neoplasms; Cost Savings; Critical Pathways; Deoxycytidine; Fluorouracil; Home Care Services; Humans; Medical Oncology; Nurse's Role; Oncology Nursing; Organizational Innovation; Patient Education as Topic; Program Development; State Medicine; Time Factors; United Kingdom | 2004 |
Implications of capecitabine (Xeloda) for cancer nursing practice.
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Communication; Deoxycytidine; Documentation; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nurse's Role; Nursing Records; Oncology Nursing; Patient Acceptance of Health Care; Patient Care Team; Patient Education as Topic; Professional Autonomy; Time Factors | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Patient Education as Topic; Syndrome | 2004 |
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2004 |
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Therapy | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Retrospective Studies; Skin Diseases; Treatment Outcome | 2005 |
Capecitabine: effective oral fluoropyrimidine chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic | 2005 |
Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Geriatrics; Humans; Male; Medical Oncology; Quality of Life | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Staging; Quality of Life; Treatment Outcome; United States | 2006 |
Uridine phosphorylase in breast cancer: a new prognostic factor?
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Enzyme Induction; Female; Floxuridine; Fluorouracil; Gene Expression Regulation; Humans; Mice; Prodrugs; Prognosis; Pyrimidinones; Treatment Outcome; Uridine Phosphorylase | 2006 |
Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2006 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2006 |
Capecitabine-docetaxel combination treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2006 |
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paraneoplastic Polyneuropathy; Prodrugs | 2007 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Oral capecitabine (Xeloda) in cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Fetus; Fluorouracil; Humans; Nurse's Role; Patient Education as Topic; Treatment Outcome | 2007 |
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Immunologic Factors; Neoplasm Metastasis; Trastuzumab | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Oncology Nursing; Patient Education as Topic; Prescription Fees | 2007 |
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Fluorouracil; Humans; Taxoids; Treatment Failure; Tubulin Modulators | 2008 |
Clinical studies with epothilones for the treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Tubulin Modulators | 2008 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Epothilones; Female; Fluorouracil; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Tubulin Modulators | 2008 |
Capecitabine: an overview of the side effects and their management.
Topics: Administration, Oral; Age Factors; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Male; Patient Education as Topic; Prodrugs | 2008 |
Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Taxoids; Tubulin Modulators | 2009 |
Oral 5-FU analogues in the treatment of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Humans; Tegafur; Uracil | 1998 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Stomach Neoplasms | 1999 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
Optimizing chemotherapy for patients with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Treatment Outcome | 1999 |
Xeloda in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
[Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2000 |
[Capecitabine for treatment of advanced breast cancers].
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2000 |
Pharmacology and clinical status of capecitabine.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Humans | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Treatment Outcome | 2001 |
Clinical status of capecitabine in the treatment of breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Forecasting; Humans; Neoplasm Recurrence, Local; Prodrugs; Treatment Outcome | 2001 |
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Treatment Outcome | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Outpatients; Tegafur; Uracil | 2001 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms | 2001 |
Capecitabine: a novel agent for the treatment of solid tumors.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Prodrugs | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
Capecitabine in breast cancer: current status.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs | 2001 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Prodrugs | 2002 |
401 trial(s) available for capecitabine and Breast Neoplasms
| Article | Year |
|---|---|
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2021 |
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2022 |
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans | 2022 |
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Male; Prospective Studies; Receptor, ErbB-2 | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Curcumin; Female; Hand-Foot Syndrome; Humans; Lawsonia Plant; Ointments | 2022 |
Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Quality of Life | 2022 |
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Fulvestrant; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Cyclin-Dependent Kinase 4; Female; Humans; Immunoconjugates; Irinotecan; Middle Aged; Receptor, ErbB-2; Vinorelbine | 2022 |
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; T-Lymphocytes, Regulatory; Vinorelbine | 2022 |
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Vinorelbine | 2022 |
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Endothelial Cells; Female; Humans; Triple Negative Breast Neoplasms | 2023 |
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Male; Middle Aged; Receptor, ErbB-2; Trastuzumab | 2023 |
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin E; Cyclin-Dependent Kinase 4; Female; Humans; Oncogene Proteins; Polo-Like Kinase 1; Proto-Oncogene Proteins; Receptor, ErbB-2; RNA, Messenger | 2023 |
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; East Asian People; Female; Humans; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2023 |
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinica
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Vinorelbine | 2023 |
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Topics: Acrylamides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Receptor, ErbB-2; Trastuzumab; Young Adult | 2023 |
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Diarrhea; Female; Hand-Foot Syndrome; Humans; Nausea; Prospective Studies; Receptor, ErbB-2; Vomiting | 2023 |
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Ibandronic Acid; Middle Aged | 2023 |
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrrolidines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2019 |
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Furans; Germ-Line Mutation; Humans; International Agencies; Ketones; Male; Middle Aged; Neoplasm Metastasis; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate; Time-to-Treatment; Vinorelbine; Young Adult | 2019 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Consolidation Chemotherapy; Diarrhea; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Oxazoles; Progression-Free Survival; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2020 |
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinorelbine | 2019 |
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Capecitabine; Case-Control Studies; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Radioisotopes; Radium; Safety; Treatment Outcome | 2020 |
Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
Topics: Abdominal Pain; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Constipation; Diarrhea; Female; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Receptor, ErbB-2; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, H
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cross-Over Studies; Estrogen Receptor alpha; Everolimus; Female; Humans; Middle Aged; Patient Preference; Prognosis; Quality of Life; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2020 |
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2020 |
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Breast Neoplasms; Capecitabine; Carcinoma; Female; Furans; Gastrointestinal Diseases; Genes, BRCA1; Genes, BRCA2; Genes, erbB-2; Germ-Line Mutation; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Single-Blind Method; Vinorelbine | 2020 |
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Italy; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Male; Middle Aged; Receptor, ErbB-2; Treatment Outcome | 2020 |
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastu
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2020 |
A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome; Vinorelbine | 2020 |
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; EGF Family of Proteins; Humans; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2021 |
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Acrylamides; Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate | 2021 |
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Furans; Gemcitabine; Germ-Line Mutation; Humans; Ketones; Middle Aged; Phthalazines; Prognosis; Receptor, ErbB-2; Survival Rate; Vinorelbine | 2021 |
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2021 |
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Quality of Life; Quinolines; Receptor, ErbB-2 | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2017 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult | 2017 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Vinblastine; Vinorelbine | 2017 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms | 2017 |
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arm; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphedema; Methotrexate; Muscle, Skeletal | 2017 |
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Breast Neoplasms; Capecitabine; Carboxylesterase; Cytidine Deaminase; Female; Humans; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2018 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prospective Studies; Radiotherapy Dosage; Response Evaluation Criteria in Solid Tumors; Triple Negative Breast Neoplasms | 2017 |
Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial.
Topics: Age Factors; Aged; Biomarkers; Breast Neoplasms; Capecitabine; Disease Progression; Doxorubicin; Female; Frailty; Geriatric Assessment; Humans; Karnofsky Performance Status; Middle Aged; Polyethylene Glycols; Treatment Outcome | 2018 |
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Topics: Adult; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab | 2018 |
Immune gene expression and response to chemotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Capecitabine; Epirubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2018 |
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Progression-Free Survival; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2018 |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Progression-Free Survival; Quality of Life; Taxoids; Treatment Outcome | 2019 |
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.
Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Longitudinal Studies; Maytansine; Models, Biological; Patient Reported Outcome Measures; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C-Reactive Protein; Capecitabine; Female; Humans; Inflammation Mediators; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Proportional Hazards Models; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2018 |
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2018 |
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyridoxine | 2018 |
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Topics: Animals; Breast Neoplasms; Capecitabine; CD11c Antigen; Cell Line, Tumor; Cell Membrane; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Ketones; Leukocytes, Mononuclear; Macrophages; Mice; Mice, SCID; Myeloid Cells; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Pilot Projects; Transcription, Genetic; Transforming Growth Factor beta | 2018 |
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Longitudinal Studies; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Netherlands; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2 | 2018 |
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Middle Aged; Progression-Free Survival; Prospective Studies | 2019 |
Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoembolization, Therapeutic; Fatigue; Female; Hand-Foot Syndrome; Hepatic Artery; Humans; Liver Neoplasms; Middle Aged; Oxaliplatin; Peripheral Nervous System Diseases; Progression-Free Survival | 2019 |
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Cell Count; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Phenotype; Prognosis; Receptor, ErbB-2; Treatment Outcome | 2019 |
Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Cost-Benefit Analysis; Disease-Free Survival; Epothilones; Female; Humans; Markov Chains; Models, Economic; Quality-Adjusted Life Years | 2019 |
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Female; Humans; Middle Aged; Progression-Free Survival; Quinolines; Receptor, ErbB-2; Survival Rate | 2019 |
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Treatment Outcome | 2019 |
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
Topics: Acrylamides; Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Rate; Tissue Distribution; Trastuzumab; Young Adult | 2019 |
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
Topics: Acrylamides; Adult; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Circulating Tumor DNA; Cohort Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2; Young Adult | 2020 |
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Survival Rate; Treatment Outcome | 2019 |
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neutropenia; Treatment Outcome | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Patient Compliance; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics | 2013 |
Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Stomatitis; Treatment Outcome | 2015 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2013 |
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Middle Aged; Pain; Pain Management; Pain Measurement; Palliative Care; Radiotherapy, Conformal | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting | 2013 |
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
[Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids | 2013 |
Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Time Factors | 2013 |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Preoperative Care; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2013 |
Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Failure; Uracil | 2014 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Lapatinib; Maytansine; Medication Adherence; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Self Report; Surveys and Questionnaires; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Estradiol; Female; Fluorouracil; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Capecitabine; Cognition Disorders; Comorbidity; Deoxycytidine; Depression; Doxorubicin; Fatigue; Female; Fluorouracil; Frail Elderly; Geriatric Assessment; Hand-Foot Syndrome; Humans; Mental Status Schedule; Palliative Care; Polyethylene Glycols; Polypharmacy; Risk Factors; Stomatitis; Treatment Outcome | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Capecitabine; Cyclic N-Oxides; Deoxycytidine; Female; Fluorouracil; Humans; Indolizines; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Pyridinium Compounds | 2014 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2014 |
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2014 |
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Netherlands; Polyethylene Glycols; Prospective Studies; Treatment Outcome | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male | 2014 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Proportional Hazards Models; Quality of Life; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Polymerase Chain Reaction; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome | 2014 |
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Pyrroles; Sunitinib | 2015 |
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Pharmacogenetics; Treatment Outcome | 2015 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Taxoids; Young Adult | 2015 |
Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Hemagglutinins; Humans; Mannose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pseudomonas aeruginosa; Receptor, ErbB-2; Safety; Salvage Therapy; Taxoids; Young Adult | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyrimidines; Tegafur | 2015 |
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Docetaxel; Female; Humans; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2015 |
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Routes; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Treatment Outcome | 2015 |
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Antioxidants; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Germany; Hand-Foot Syndrome; Humans; Incidence; Keratolytic Agents; Male; Middle Aged; Ointments; Primary Prevention; Quality of Life; Severity of Illness Index; Skin Cream; Surveys and Questionnaires; Time Factors; Treatment Failure; Urea | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; China; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged | 2015 |
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Odds Ratio; Taxoids; Treatment Outcome | 2015 |
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Feasibility Studies; Female; Furans; Humans; Ketones; Middle Aged; Neoplasm Staging; Postmenopause | 2016 |
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Middle Aged; Neoplasm Staging; Physicians; Polyethylene Glycols; Taxoids | 2015 |
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Female; Furans; Humans; Ketones; Middle Aged; Quality of Life | 2015 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome | 2016 |
Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2016 |
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
[Complex treatment of breast cancer patients with brain metastases].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Middle Aged; Russia; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunization; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine | 2016 |
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Protocols; Colorectal Neoplasms; Drug Dosage Calculations; Enhancer Elements, Genetic; Female; Genotype; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pharmacogenomic Testing; Polymorphism, Genetic; Thymidylate Synthase | 2016 |
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Carboplatin; Clinical Protocols; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Female; Genetic Predisposition to Disease; Humans; Mutation; Netherlands; Phenotype; Phthalazines; Piperazines; Receptor, ErbB-2; Research Design; Time Factors; Treatment Outcome | 2016 |
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Furans; Humans; Ketones; Prognosis | 2015 |
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate | 2016 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Young Adult | 2016 |
Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Vinblastine; Vinorelbine | 2017 |
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Quality of Life; Receptor, ErbB-2; Retreatment; Treatment Outcome | 2016 |
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Retreatment; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ramucirumab; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2008 |
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2008 |
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Hypertension; Middle Aged; Treatment Outcome | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult | 2008 |
XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor | 2008 |
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2009 |
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Receptor, ErbB-2; Taxoids | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; International Agencies; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Quinazolines | 2009 |
A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Drug Costs; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Taxoids | 2009 |
Adjuvant chemotherapy in older women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Survival Analysis | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2009 |
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2010 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2010 |
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epidemiologic Methods; Epothilones; ErbB Receptors; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Neoplasm Metastasis | 2010 |
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2 | 2009 |
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Period; Taxoids; Treatment Outcome | 2010 |
Capecitabine in the routine treatment of advanced breast cancer: results from a non-interventional observational study in 876 [corrected] patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Treatment Outcome; United States | 2010 |
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Receptor, ErbB-2; Taxoids | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids | 2010 |
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Home Care Services; Humans; Male; Middle Aged; Palliative Care; Quality of Life | 2009 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cluster Analysis; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Pilot Projects; Taxoids | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; International Agencies; Liver Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Soft Tissue Neoplasms; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2010 |
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2010 |
Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Retrospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Thalidomide | 2010 |
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Indoles; Kaplan-Meier Estimate; Pyrroles; Sunitinib | 2010 |
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Drug Monitoring; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Linear Models; Logistic Models; Mastectomy; Medication Adherence; Micro-Electrical-Mechanical Systems; Neoplasm Staging; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Syndrome; Time Factors; Treatment Outcome | 2010 |
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; South America; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; United States | 2010 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; China; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Retreatment; Taxoids | 2010 |
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab | 2010 |
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Germany; Humans; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Phenotype; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | 2011 |
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden | 2011 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Ventricular Function, Left | 2010 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Quality of Life | 2010 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Mexico; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placebo Effect; Proportional Hazards Models; Risk Assessment; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2010 |
Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients (aged 55-70) with stage IIa breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Cyclophosphamide; Cytarabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Pyridoxine; Vitamin B Complex | 2010 |
[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Vinblastine; Vinorelbine | 2010 |
Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2010 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis | 2011 |
Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Vinblastine; Vinorelbine | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Quality of Life; Risk Assessment; Risk Factors; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2011 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; DNA Mutational Analysis; Docetaxel; Female; Fluorouracil; Genomics; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2012 |
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 2011 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2011 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Exanthema; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-2; Remission Induction | 2011 |
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Remission Induction; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Europe; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2012 |
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Taxoids; Young Adult | 2012 |
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; Exons; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Confidence Intervals; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Models, Economic; Probability; Quality-Adjusted Life Years; Quinazolines; State Medicine; Trastuzumab; United Kingdom; Women's Health | 2012 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Molecular Targeted Therapy; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Treatment Outcome | 2012 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Young Adult | 2012 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged | 2011 |
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine | 2012 |
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Middle Aged | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Young Adult | 2012 |
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Mucin-1; Prospective Studies | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Trastuzumab; Vinblastine; Vinorelbine | 2012 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2012 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Quinolones; Taxoids; Treatment Outcome | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Survival Rate; Taxoids; Treatment Outcome; Tubulin Modulators | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Medication Adherence; Methotrexate; Patient Compliance | 2012 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Placebos; Pyridoxine | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2012 |
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Tubulin; Vinblastine; Young Adult | 2013 |
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Tablets; Therapeutic Equivalency | 2013 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyglutamic Acid; Proportional Hazards Models; Treatment Outcome | 2014 |
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2013 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Taxoids | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Patient Compliance; Treatment Outcome | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biotransformation; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Japan; Metabolic Clearance Rate; Middle Aged; Tissue Distribution; White People | 2003 |
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 5; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Phosphoric Diester Hydrolases; Prodrugs; Sulindac | 2003 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Taxoids; Treatment Outcome | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Confidence Intervals; Data Interpretation, Statistical; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2004 |
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2004 |
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Nails; Paclitaxel; Skin; Switzerland; Treatment Outcome | 2004 |
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Middle Aged; Neutropenia; Outpatients; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2004 |
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life | 2005 |
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Kidney Diseases; Treatment Outcome | 2005 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Middle Aged | 2005 |
Capecitabine plus docetaxel combination therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Quality of Life; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathy, Dilated; Coronary Stenosis; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Glutamates; Guanine; Humans; Infusions, Intravenous; Middle Aged; Pemetrexed; Taxoids; Treatment Outcome | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Middle Aged; Quality of Life; Survival Rate | 2005 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast Neoplasms; Breath Tests; Capecitabine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Deoxycytidine; Erythromycin; Female; Fluorouracil; Genotype; Humans; Maximum Tolerated Dose; Middle Aged; Polymorphism, Restriction Fragment Length; Vinblastine; Vinorelbine | 2006 |
Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2006 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prodrugs; Sample Size; Survival Rate; Treatment Outcome | 2006 |
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Oligodeoxyribonucleotides; Oligonucleotides, Antisense; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2006 |
Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Vinblastine; Vinorelbine | 2006 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2006 |
Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Nausea; Temozolomide; Treatment Outcome; Vomiting | 2006 |
[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leukopenia; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Vinblastine; Vinorelbine | 2006 |
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Premedication; Prospective Studies; Radionuclide Imaging; Remission Induction; Taxoids | 2006 |
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Prodrugs; Survival Analysis; Treatment Outcome | 2006 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Heart Diseases; Humans; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Prodrugs; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lymph Node Excision; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone | 2007 |
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2007 |
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Taxoids | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Heart Diseases; Humans; Infusions, Intravenous; Japan; Middle Aged; Trastuzumab; Treatment Outcome | 2008 |
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Germany; Humans; Middle Aged; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2007 |
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2007 |
Capecitabine therapy of central nervous system metastases from breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Meningeal Neoplasms; Middle Aged; Prodrugs; Retrospective Studies; Treatment Outcome | 2007 |
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel | 2008 |
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2008 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure; Vinblastine; Vinorelbine | 2007 |
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Vinblastine; Vinorelbine | 2008 |
Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Pilot Projects; Sample Size; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2007 |
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prodrugs; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate | 2008 |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged | 2007 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Taxoids; Treatment Outcome; Ultrasonography, Mammary; Vinblastine; Vinorelbine | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Models, Biological; Prodrugs; Soft Tissue Neoplasms; Thoracic Neoplasms | 2008 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Maximum Tolerated Dose; Skin Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Time Factors; Treatment Failure | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2009 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
[Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Recurrence | 2002 |
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
514 other study(ies) available for capecitabine and Breast Neoplasms
| Article | Year |
|---|---|
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Receptor, ErbB-2; Retrospective Studies; Triple Negative Breast Neoplasms | 2021 |
Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Furans; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2022 |
Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Triple Negative Breast Neoplasms | 2022 |
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Retrospective Studies | 2021 |
Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Male; New Zealand; Risk Factors | 2021 |
The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Hormones; Humans; Immunoconjugates; Ki-67 Antigen; Lapatinib; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2022 |
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Furans; Humans; Ketones; Leukocyte Count; Middle Aged; Prognosis; Retrospective Studies | 2022 |
Adjuvant capecitabine for early triple-negative breast cancer: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Survey of US Medical Oncologists' Practices and Beliefs Regarding
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Oncologists | 2022 |
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Topics: Ado-Trastuzumab Emtansine; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab | 2022 |
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2 | 2022 |
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2022 |
Capecitabine-induced severe diabetes and hypokalemia: a case report.
Topics: Blood Glucose; Breast Neoplasms; Capecitabine; Diabetes Mellitus; Female; Fluorouracil; Humans; Hypokalemia; Insulin; Mastectomy; Middle Aged; Potassium | 2022 |
Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
Topics: Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Triple Negative Breast Neoplasms | 2022 |
Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen receptor
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2022 |
Denied access to smartphone with fingerprint sensor in a patient with cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dermatoglyphics; Female; Fingers; Humans; Smartphone | 2022 |
Implications of the PEARL trial from the low- to middle-income countries' perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Developing Countries; Female; Health Care Costs; Humans; Income | 2022 |
Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deep Learning; Female; Humans; Hypertension, Portal; Lapatinib; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Spleen; Splenomegaly; Tomography, X-Ray Computed | 2022 |
Combination Treatment of Vinorelbine With Oral Cyclophosphamide or Capecitabine or Both Might Overcome Cross-resistance Against Eribulin in Advanced Breast Cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Fluorouracil; Furans; Humans; Ketones; Treatment Outcome; Vinblastine; Vinorelbine | 2022 |
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Hospitals; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2022 |
Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2 | 2022 |
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Paclitaxel; Quality of Life; Taxoids | 2023 |
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Patient Reported Outcome Measures; Pilot Projects | 2022 |
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2023 |
Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Insurance Coverage; Lapatinib; Neoplasms, Second Primary; Trastuzumab | 2022 |
Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer.
Topics: Acrylamides; Aminoquinolines; Breast Neoplasms; Capecitabine; Enzyme Inhibitors; Female; Humans; Receptor, ErbB-2; Risk Factors | 2022 |
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Trastuzumab; Vinorelbine | 2022 |
Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lapatinib; Quality-Adjusted Life Years; Receptor, ErbB-2 | 2022 |
T-DXd Keeps Shining in Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Capecitabine; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Retrospective Studies; Trastuzumab | 2023 |
Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Pharmaceutical Preparations; Prospective Studies | 2023 |
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2022 |
Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer.
Topics: Acrylamides; Aminoquinolines; Breast Neoplasms; Capecitabine; Female; Humans | 2023 |
The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2023 |
Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases-Reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Disease Progression; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies | 2023 |
[A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cyclophosphamide; Docetaxel; Female; Humans; Liver Neoplasms; Mastectomy; Quality of Life | 2023 |
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Humans; Receptor, ErbB-2; Retrospective Studies | 2023 |
[A Case of COVID-19 Infection during Postoperative Chemotherapy for Breast Cancer Treated with Antibody Cocktail Therapy to Prevent Disease Aggravation].
Topics: Breast Neoplasms; Capecitabine; Combined Antibody Therapeutics; COVID-19; COVID-19 Drug Treatment; Female; Humans; Mastectomy; Middle Aged | 2023 |
Pyrotinib versus lapatinib in HER2-positive breast cancer.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Humans; Lapatinib; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2019 |
Eruptive palmoplantar lesions induced by capecitabine: report of a case evaluated with dermoscopy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dermoscopy; Diagnosis, Differential; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Melanoma; Middle Aged; Neoplasms, Second Primary; Skin Neoplasms | 2019 |
Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Receptors, Estrogen | 2019 |
Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lapatinib; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Capecitabine-loaded anti-cancer nanocomposite hydrogel drug delivery systems:
Topics: Animals; Antineoplastic Agents; Bentonite; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Liberation; Female; Mice; Mice, Inbred BALB C; Nanocomposites; Nanogels; Polyvinyl Alcohol; Tumor Burden | 2020 |
Radiation recall dermatitis in response to adjuvant capecitabine immediately following postoperative radiotherapy in a patient with breast cancer.
Topics: Breast Neoplasms; Capecitabine; Female; Humans; Radiodermatitis; Radiotherapy, Adjuvant | 2020 |
Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Topics: Activities of Daily Living; Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cross-Sectional Studies; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Surveys and Questionnaires; Taiwan | 2019 |
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Genotype; Hand-Foot Syndrome; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2019 |
[A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.]
Topics: Administration, Metronomic; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lymphatic Metastasis; Skin Neoplasms; Treatment Outcome; Vinorelbine | 2019 |
Endocrine-based therapy versus chemotherapy in advanced breast cancer.
Topics: Androstadienes; Breast Neoplasms; Capecitabine; Female; Gonadotropin-Releasing Hormone; Humans; Piperazines; Pyridines | 2019 |
Capecitabine-Related Eruption Mimicking Dermatomyositis in 2 Patients With Metastatic Breast Cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dermatomyositis; Diagnosis, Differential; Female; Hand-Foot Syndrome; Humans; Middle Aged | 2020 |
Role of Capecitabine in Early Breast Cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Triple Negative Breast Neoplasms | 2020 |
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Middle Aged; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Taiwan; Trastuzumab | 2020 |
[A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.]
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lymphatic Metastasis; Skin Neoplasms; Treatment Outcome; Vinorelbine | 2019 |
Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real-World Evidence Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Palliative Care | 2020 |
Pharmacotherapeutics of capecitabine and trastuzumab in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Trastuzumab; Treatment Outcome | 2020 |
HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chitosan; Female; Humans; Liposomes; Peptides; Receptor, ErbB-2 | 2020 |
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine.
Topics: Adult; Aged; Biomarkers; Breast Neoplasms; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Retrospective Studies; Thymidylate Synthase | 2020 |
[Stage Ⅳ Breast Cancer with Difficulty in Initiating Chemotherapy-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Trastuzumab | 2019 |
Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Markov Chains; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2020 |
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.
Topics: Adult; Breast; Breast Neoplasms; Capecitabine; Case-Control Studies; Chemoradiotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; China; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Vinorelbine; Young Adult | 2020 |
Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Humans; Receptor, ErbB-2; Reference Standards; Triple Negative Breast Neoplasms | 2020 |
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Ferredoxin-NADP Reductase; Follow-Up Studies; Genotype; Germ-Line Mutation; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Quality of Life | 2020 |
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Immune Checkpoint Inhibitors; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Comment on "Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity".
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Feasibility Studies; Humans; Radiotherapy, Adjuvant | 2020 |
Radiation recall myelitis following capecitabine: First case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma; Combined Modality Therapy; Docetaxel; Drug Substitution; Female; Humans; Hyperbaric Oxygenation; Letrozole; Middle Aged; Myelitis; Myositis; Prednisolone; Radiodermatitis; Radiotherapy, Adjuvant; Spinal Cord; Spinal Neoplasms; Thoracic Vertebrae | 2020 |
Therapy for HER2-Positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Humans; Receptor, ErbB-2; Trastuzumab | 2020 |
Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.
Topics: Acrylamides; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Receptor, ErbB-2 | 2020 |
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Databases, Factual; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Retrospective Studies; Vinorelbine | 2020 |
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Proportional Hazards Models; Receptor, ErbB-2; Vinorelbine | 2020 |
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Liver; Lung Neoplasms; Retrospective Studies; Survival Analysis | 2020 |
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Maintenance; Triple Negative Breast Neoplasms | 2021 |
[Ⅰ.Capecitabine for Adjuvant Therapy in Breast Cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Treatment Outcome | 2020 |
[Disseminated Bone Marrow Carcinomatosis from Breast Cancer Improved by Capecitabine-A Clinical Case Report].
Topics: Bone Marrow; Breast Neoplasms; Capecitabine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.
Topics: Aromatase Inhibitors; Breast Neoplasms; Capecitabine; EGF Family of Proteins; Humans; Piperazines; Pyridines | 2021 |
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Quinolines; Receptor, ErbB-2 | 2021 |
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Drug Costs; Female; Furans; Health Care Costs; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Quality of Life; Taiwan; Treatment Outcome | 2021 |
Capecitabine-induced hyperosmolar hyperglycaemic state.
Topics: Aged; Blood Glucose; Breast Neoplasms; Capecitabine; Diabetes Mellitus; Female; Humans; Hyperglycemia; Hyperglycemic Hyperosmolar Nonketotic Coma | 2021 |
Neratinib: an option for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Cost-Benefit Analysis; Female; Humans; Quality-Adjusted Life Years; Receptor, ErbB-2 | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
Topics: Adult; Aged; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Necrosis; Neoplasm Staging; Radiation Injuries; Radiosurgery; Retrospective Studies; Treatment Outcome | 2021 |
Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fluorouracil; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays | 2021 |
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult | 2021 |
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Vinorelbine | 2022 |
Capecitabine-induced lichenoid drug eruption: a case report.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Drug Eruptions; Female; Forearm; Humans; Lichenoid Eruptions; Middle Aged | 2017 |
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Genotype; Humans; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies | 2017 |
Capecitabine-induced acute toxic leukoencephalopathy.
Topics: Antimetabolites, Antineoplastic; Bone and Bones; Breast Neoplasms; Capecitabine; Female; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Middle Aged; Pyramidal Tracts | 2017 |
Adjuvant capecitabine for HER2-negative breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2017 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Coronary Vasospasm; Drug Combinations; Drug Substitution; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
Breast cancer: T-DM1 - an important agent in the history of breast cancer management.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Capecitabine; Humans; Lapatinib; Maytansine; Trastuzumab | 2017 |
Adjuvant Capecitabine for Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2017 |
Adjuvant Capecitabine for Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2017 |
Adjuvant Capecitabine for Breast Cancer.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Capecitabine; Humans | 2017 |
Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Decision Making; Female; Humans; Informed Consent; Morpholines; Motivation; Neoplasm Metastasis; Protein Kinase Inhibitors; Qualitative Research; Research Subjects | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Mastectomy; Middle Aged; Nausea; Neutropenia; Pharmacogenomic Testing; Polymorphism, Genetic; Prodrugs; Thymidylate Synthase; Vomiting | 2018 |
Eruptive nevi in a patient with metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Drug Eruptions; Female; Foot Diseases; Hand; Humans; Middle Aged; Nevus, Pigmented; Skin Neoplasms | 2017 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?-Reply.
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; C-Reactive Protein; Capecitabine; Curcuma; Curcumin; Female; Gastrointestinal Neoplasms; Hand-Foot Syndrome; Humans; Interleukin-6; Male; Middle Aged; Phytotherapy; Pilot Projects; Quality of Life; Serum Albumin; Surveys and Questionnaires; Tumor Necrosis Factor-alpha | 2018 |
Reversible severe fatty liver induced by capecitabine: A case report.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Fatty Liver; Female; Humans; Remission, Spontaneous; Tomography, X-Ray Computed | 2017 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP1A1; Docetaxel; Female; Genetic Markers; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Progression-Free Survival; Survival Analysis; Thiotepa | 2018 |
Photosensitive lichenoid skin reaction to capecitabine.
Topics: Administration, Topical; Aged; Breast Neoplasms; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lichenoid Eruptions; Photosensitivity Disorders; Steroids | 2017 |
Capecitabine-Related Neurotoxicity Presenting as Oromandibular Dystonia.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dystonia; Female; Humans; Magnetic Resonance Imaging; Mandible | 2018 |
Emilia: use cunning to survive cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2018 |
[Long-Term Capecitabine Therapy Was Successful for Locally Advanced Breast Cancer Patient - Report of a Case].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy, Large-Core Needle; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Staging; Time Factors; Treatment Outcome | 2018 |
A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Drug Industry; Female; Humans; Periodicals as Topic; Treatment Outcome | 2018 |
Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Polarity; Chemokines, CC; Chemotherapy, Adjuvant; Chitinases; Cyclophosphamide; DNA Topoisomerases, Type II; Doxorubicin; Female; Fluorouracil; Gene Amplification; Gene Expression; Humans; Macrophage Activation; Macrophages; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins | 2018 |
Is there room for another HER2-targeting drug?
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Humans; Receptor, ErbB-2; Trastuzumab | 2018 |
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |
Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Pyrimidines; Retrospective Studies | 2018 |
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cohort Studies; Colorectal Neoplasms; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Surveys and Questionnaires | 2018 |
Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016).
Topics: Aged; Anthracyclines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Capecitabine; Cluster Analysis; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Patient Compliance; Patient Selection; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Vinorelbine | 2018 |
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis | 2018 |
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carboplatin; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2018 |
Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Quality of Life; Tegafur; Treatment Outcome | 2018 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2019 |
Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Humans; Quinolines; Receptor, ErbB-2 | 2019 |
Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2019 |
Neratinib and capecitabine for breast cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Female; Humans; Quinolines; Receptor, ErbB-2; Treatment Outcome | 2019 |
Brain metastases respond to neratinib plus capecitabine.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Humans; Quinolines; Receptor, ErbB-2 | 2019 |
Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?
Topics: Breast Neoplasms; Capecitabine; Fluorouracil; Humans; Quality of Life; Retrospective Studies; Vinblastine; Vinorelbine | 2019 |
Case of capecitabine-induced severe erosional radiation recall dermatitis in a patient with breast cancer.
Topics: Acyclovir; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Female; gamma-Globulins; Humans; Lymph Node Excision; Mastectomy, Segmental; Radiodermatitis; Skin | 2019 |
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biology; Biomedical Research; Breast Neoplasms; Capecitabine; Digestive System Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; France; Genotype; Health Care Surveys; Humans; Oncologists; Otorhinolaryngologic Neoplasms; Pharmacovigilance; Practice Guidelines as Topic; Pyrimidines; Reimbursement Mechanisms | 2019 |
Silver nanoparticle/capecitabine for breast cancer cell treatment.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Capecitabine; Cell Proliferation; Humans; MCF-7 Cells; Metal Nanoparticles; Silver | 2019 |
[Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Receptor, ErbB-2; Trastuzumab | 2013 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Patient Participation; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2002 |
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cognition; Deoxycytidine; Female; Fluorouracil; Humans; Neuropsychological Tests; Quality of Life; Risk Factors; Surveys and Questionnaires | 2013 |
Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslipidemias; Female; Fluorouracil; Humans; Hypertriglyceridemia; Israel; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Risk Factors | 2013 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Interleukin-10; Mexico; Middle Aged; Paclitaxel; Polymorphism, Genetic; Spain; Tamoxifen | 2013 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Recombinant Proteins; Survival Analysis; Taxoids; Young Adult | 2013 |
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
Topics: Antineoplastic Agents; Articulation Disorders; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Trastuzumab-induced systemic capillary leak syndrome in a breast cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Capillary Leak Syndrome; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Trastuzumab | 2014 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
Epicardial coronary artery spasm as cause of capecitabine-induced tako tsubo cardiomyopathy.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Coronary Angiography; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Takotsubo Cardiomyopathy | 2014 |
Preparation and characterization of a gastric floating dosage form of capecitabine.
Topics: Acrylic Resins; Alginates; Breast Neoplasms; Capecitabine; Chemistry, Pharmaceutical; Deoxycytidine; Drug Dosage Calculations; Female; Fluorouracil; Gastrointestinal Diseases; Glucuronic Acid; Hexuronic Acids; Humans; Hypromellose Derivatives; Methylcellulose; Sodium Bicarbonate; United States; United States Food and Drug Administration | 2013 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2014 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Muscle, Skeletal; Stomach Neoplasms | 2013 |
Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Precision Medicine; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genome-Wide Association Study; Genomics; Hand-Foot Syndrome; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide | 2014 |
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Community Mental Health Centers; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Medical Oncology; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine | 2015 |
Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Data Collection; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Patient Preference | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Stomach Neoplasms | 2013 |
Oral chemotherapy in elderly women with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Infusions, Intravenous; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2014 |
[A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Trastuzumab | 2014 |
[Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases].
Topics: Anticonvulsants; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Middle Aged; Phenytoin; Seizures; Valproic Acid | 2014 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2014 |
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Phone; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects | 2014 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Erythrocyte Indices; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2013 |
Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2015 |
[Hepatotoxicity of acetaminophen in a patient treated with capecitabine due to breast cancer].
Topics: Acetaminophen; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Overdose; Female; Fluorouracil; Humans; Liver; Middle Aged; Virus Diseases | 2014 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Topics: Animals; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Mice, Inbred BALB C; Tubulin Modulators; Tumor Microenvironment; Vascular Remodeling; Xenograft Model Antitumor Assays | 2014 |
Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2014 |
[Survey of the current status of capecitabine-induced hypertriglyceridemia].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2014 |
Length of chemotherapy and use of bevacizumab for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2014 |
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2015 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Survival Rate; Vitamin B Complex | 2014 |
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Germany; Hand-Foot Syndrome; Humans; Middle Aged; Product Surveillance, Postmarketing; Quality of Life; Risk Assessment; Surveys and Questionnaires | 2014 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorometholone; Fluoroquinolones; Fluorouracil; Gatifloxacin; Hand-Foot Syndrome; Humans; Lacrimal Duct Obstruction | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chromatin Assembly and Disassembly; DNA Repair; Female; Genetic Variation; Genotype; Humans; Neoplasm Metastasis; Phenotype; Phosphoproteins; Proteome; Proteomics; Receptors, Estrogen; Treatment Outcome | 2015 |
Images in clinical medicine. Loss of fingerprints.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Female; Fingers; Fluorouracil; Hand-Foot Syndrome; Humans | 2015 |
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2015 |
Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301).
Topics: Age Factors; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Outcome Assessment, Health Care; Social Support; Surveys and Questionnaires; Survival Analysis; Time Factors | 2016 |
Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Canada; Capecitabine; Delivery of Health Care; Female; Health Care Costs; Humans; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Qualitative Research | 2015 |
A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-Administered Term or the Discontinuation Term of Capecitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Retrospective Studies; Treatment Outcome; Warfarin | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Humans; Liver Neoplasms; Mastectomy; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Retreatment | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Diarrhea; Disease Progression; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Retrospective Studies; Survival Rate; Triazoles | 2015 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Taxoids; Tegafur | 2015 |
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cadherins; Capecitabine; Carcinoma, Lobular; Female; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Quinazolines; Radiography; Receptor, ErbB-2; Treatment Outcome | 2016 |
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Dihydrouracil Dehydrogenase (NADP); Fatal Outcome; Female; Humans; Lymphatic Metastasis; Mutation; Trastuzumab | 2016 |
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies | 2016 |
Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carrier Proteins; Caspase 3; Caspase 7; Cisplatin; Cytokines; Cytoskeletal Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Interferon-beta; Interferon-gamma; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Nude; Mitochondrial Proteins; Myxovirus Resistance Proteins; Neoplasm Transplantation; Phosphorylation; Real-Time Polymerase Chain Reaction; Receptors, Estrogen; RNA-Binding Proteins; Signal Transduction; STAT1 Transcription Factor; Ubiquitins; Xenograft Model Antitumor Assays | 2016 |
NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Humans; Maytansine; Practice Guidelines as Topic; Receptor, ErbB-2; Trastuzumab; United Kingdom | 2016 |
[Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Capecitabine; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis | 2016 |
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Breast Neoplasms; Capecitabine; Cell Proliferation; Chromatin Immunoprecipitation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Phosphorylase; Tumor Cells, Cultured; Valproic Acid; Xenograft Model Antitumor Assays | 2016 |
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Creatinine; Cyclophosphamide; Female; Fluorouracil; Humans; Kidney Function Tests; Methotrexate; Prognosis; Renal Insufficiency; Survival Rate; Tamoxifen; Treatment Outcome | 2016 |
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; DNA Mutational Analysis; Docetaxel; Epirubicin; Gene Expression; Humans; Middle Aged; Mutation; Phosphoproteins; PTEN Phosphohydrolase; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Treatment Outcome | 2016 |
[A Case of an Older Patient with Metastatic Breast Cancer Effectively Treated with Capecitabine, with Achievement of cCR].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Recurrence | 2015 |
Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
Topics: Androgen Antagonists; Androgens; Apocrine Glands; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Female; Humans; Hydrocortisone; Middle Aged; Mucin-1; Postmenopause; Receptors, Androgen | 2016 |
[Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Discriminant Analysis; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Psychometrics; Reproducibility of Results; Surveys and Questionnaires | 2016 |
Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
Topics: Administration, Oral; Ambulatory Care Facilities; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost Savings; Costs and Cost Analysis; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Medication Errors; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Care; Patient Compliance; Patient Education as Topic; Rectal Neoplasms | 2016 |
[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2016 |
[A clinical case of combined treatment of a patient with breast cancer and metastases to the brain and meninges].
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Female; Humans; Meningeal Neoplasms; Neoplasm Metastasis | 2016 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
[Breast Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine Monotherapy after Failure of Combination Therapy Comprising Bevacizumab and Paclitaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Liver Neoplasms; Paclitaxel; Salvage Therapy | 2016 |
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Disease-Free Survival; Female; Hormone Antagonists; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Italy; Lapatinib; Logistic Models; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2016 |
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Predictive Value of Tests | 2016 |
[A case of palmoplantar dysesthesia syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Diagnosis, Differential; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Syndrome | 2016 |
Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.
Topics: Aged; Breast Neoplasms; Capecitabine; Estrogen Antagonists; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2016 |
Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Drug Administration Schedule; Exons; Female; Gene Expression; Gene Frequency; Genotype; Heterozygote; Humans; Introns; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies; Sequence Analysis, DNA | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Humans; Lapatinib; Markov Chains; Maytansine; Middle Aged; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States | 2016 |
Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment.
Topics: Breast Neoplasms; Capecitabine; Humans; Neoadjuvant Therapy; Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2016 |
Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation.
Topics: Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Female; Humans; Male; Pharmacogenetics; Thymidylate Synthase | 2016 |
Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Hungary; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids | 2017 |
Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Capecitabine; Cardiotoxicity; Chest Pain; Comorbidity; Denmark; Female; Humans; Incidence; Middle Aged; Myocardial Infarction; Neoplasm Metastasis; Retrospective Studies; Risk Factors | 2016 |
First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Taxoids; Vinblastine; Vinorelbine | 2017 |
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study.
Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2016 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
New Data About First-line All-oral Vinorelbine and Capecitabine in HER2-negative Metastatic Breast Cancer Confirms Results of Meta-analysis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Meta-Analysis as Topic; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Large bowel perforation associated with capecitabine treatment for breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Perforation; Sigmoid Diseases | 2008 |
Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cholesterol; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Middle Aged; Prodrugs; Triglycerides | 2009 |
New treatment strategies provide more options for patients with breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Female; Fluorouracil; Humans; Imidazoles; Zoledronic Acid | 2008 |
Capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Coronary Vasospasm; Deoxycytidine; Echocardiography; Electrocardiography; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2008 |
Drug development in the targeted therapy era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disclosure; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Quinazolines; Receptor, ErbB-2 | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pleural Neoplasms; Prodrugs; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2009 |
[Clinical effect and positioning of capecitabine for metastatic breast carcinoma].
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
[Management of hand-foot syndrome in patient treated with capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Nervous System Diseases; Skin Diseases; Syndrome | 2008 |
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Thymidine Phosphorylase; Time Factors; Treatment Outcome; Ubiquitin-Protein Ligases | 2009 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Neoplasms, Second Primary; Paclitaxel; Receptor, ErbB-2; Remission Induction; Skin Neoplasms; Survival Rate; Trastuzumab | 2008 |
[A recurrent case of lipid-secreting carcinoma of the breast successfully treated with capecitabine].
Topics: Biopsy; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lipid Metabolism; Mammography; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2009 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis | 2008 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Remission Induction; Survival Rate; Taxoids; Vomiting | 2008 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate; Taxoids | 2008 |
[A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Remission Induction; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2009 |
[A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy; Lymphatic Metastasis; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2009 |
A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Hyperpigmentation | 2009 |
Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chest Pain; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Myocardial Ischemia; Nitroglycerin; Prognosis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Epothilones; Female; Fluorouracil; Humans; Quality-Adjusted Life Years | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Muscle, Skeletal; Muscular Diseases; Neoplasm Metastasis; Prospective Studies | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Nursing considerations for capecitabine-based combination therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Monitoring; Fluorouracil; Humans; Oncology Nursing; Patient Education as Topic; Safety | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
[Palliative chemotherapy for metastatic breast cancer with capecitabine].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
[A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Positron-Emission Tomography; Taxoids; Thoracic Neoplasms; Thoracic Wall; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermoscopy; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Pigmentation Disorders; Tongue Diseases | 2009 |
Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer.
Topics: Adolescent; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Health Status; Humans; Middle Aged; Multicenter Studies as Topic; New Zealand; Outcome Assessment, Health Care; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sickness Impact Profile; Surveys and Questionnaires; Survival Analysis; Young Adult | 2009 |
[Coronary artery disease attack caused by cytotoxic chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Male; Middle Aged | 2009 |
Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
Topics: Administration, Buccal; Antimetabolites, Antineoplastic; Betamethasone; Breast Neoplasms; Capecitabine; Chlorhexidine; Deoxycytidine; Female; Fluorouracil; Glucocorticoids; Humans; Middle Aged; Skin; Stomatitis | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Palliative Care; Pemetrexed; Prospective Studies; Radiation Tolerance; Radiotherapy Dosage; Young Adult | 2010 |
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Middle Aged; RNA, Messenger; Thymidine Phosphorylase | 2009 |
Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Taxoids | 2009 |
Severe palmar-plantar erytrodysesthesia after treatment with capecitabine.
Topics: Antineoplastic Agents; Blister; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged | 2010 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Goserelin; Hematoma, Subdural, Intracranial; Humans; Indoles; Letrozole; Leukopenia; Nitriles; Pyrroles; Skull; Sunitinib; Triazoles | 2009 |
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mucin-1; Quinazolines; Receptor, ErbB-2; Thrombocytopenia; Trastuzumab | 2009 |
Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Decision Making; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Patient Satisfaction; Quality of Life; Surveys and Questionnaires | 2010 |
Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Socioeconomic Factors; Treatment Outcome; United Kingdom | 2010 |
Chemotherapy in older women with breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Radiotherapy, Adjuvant | 2009 |
Chemotherapy in older women with breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Receptors, Estrogen | 2009 |
Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Infusions, Intravenous; Linear Models; Middle Aged; SEER Program; Taxoids | 2009 |
[A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Skin Ulcer | 2009 |
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Therapy; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Methotrexate; Neoplasm Recurrence, Local; Neutropenia; Patient Compliance; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Therapeutic Equivalency | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neoplasm Metastasis; Pyridoxine; Retrospective Studies; Vitamin B Complex | 2010 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dideoxynucleosides; Fluorouracil; Humans; Positron-Emission Tomography; Regional Blood Flow; Thymidylate Synthase | 2009 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Taxoids; Treatment Outcome | 2009 |
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Quality of Life; Retrospective Studies; Time Factors; Treatment Failure | 2009 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Cost comparison of capecitabine in patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Taxoids; United States | 2010 |
Capecitabine cardiac toxicity presenting as effort angina: a case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cardiovascular Agents; Coronary Vasospasm; Deoxycytidine; Echocardiography, Doppler, Color; Echocardiography, Doppler, Pulsed; Electrocardiography; Female; Fluorouracil; Humans; Middle Aged | 2010 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Papillary; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epothilones; Female; Fluorouracil; Follow-Up Studies; Humans; Long-Term Care; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
[Long-term response of liver metastases of breast cancer to capecitabine--case report].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2010 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
[More effective positioning of capecitabine for advanced and metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Survival Rate | 2010 |
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Skin Neoplasms; Taxoids; Tomography, X-Ray Computed; Vitamin B 6 | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Neoplasms; Risk Factors; Stomach Neoplasms | 2010 |
Trastuzumab beyond progression: a cost-utility analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lymphatic Metastasis; Markov Chains; Prognosis; Quality-Adjusted Life Years; Sensitivity and Specificity; Survival Rate; Time Factors; Trastuzumab | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
Capecitabine dosing is not yet optimized for breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Prodrugs | 2010 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2010 |
Overcoming radiation resistance in inflammatory breast cancer.
Topics: Breast Neoplasms; Capecitabine; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2010 |
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Mice; Models, Theoretical; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2010 |
Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer.
Topics: Aged; Aortic Aneurysm, Abdominal; Aortic Dissection; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Treatment Outcome | 2010 |
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Germany; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Patient Care Team; Statistics as Topic; Statistics, Nonparametric | 2011 |
Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Qualitative Research; Risk Factors | 2011 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2010 |
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2012 |
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation | 2011 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2010 |
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate | 2011 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2010 |
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2011 |
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; France; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2011 |
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neuropilin-1; Vascular Endothelial Growth Factor C | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; E2F Transcription Factors; Erythema; Female; Fluorouracil; Foot Dermatoses; Genetic Association Studies; Genetic Predisposition to Disease; Hand Dermatoses; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Pain; Polymorphism, Single Nucleotide; Prodrugs; Promoter Regions, Genetic; Sequence Analysis, DNA; Syndrome; Transcription, Genetic | 2011 |
[Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphangitis; Middle Aged; Pleurisy; Quality of Life; Recurrence; Tomography, X-Ray Computed | 2011 |
Is capecitabine efficacious in triple negative metastatic breast cancer?
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2010 |
Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Survival; Deoxycytidine; Drug Stability; Female; Fluorouracil; Inhibitory Concentration 50; Liquid Crystals; Mice; Phase Transition; Prodrugs; Treatment Outcome | 2011 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2011 |
Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Japan; Maximum Tolerated Dose; Models, Statistical; Retrospective Studies | 2011 |
Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Treatment Outcome | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Patient Compliance; Prospective Studies; Self Report; Stomatitis; Vomiting | 2011 |
Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Topics: Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Phosphorylase; Vorinostat | 2011 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2011 |
Capecitabine-phenytoin interaction is dose dependent with an unexpected time course.
Topics: Aged; Anticonvulsants; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Epilepsy; Female; Fluorouracil; Humans; Phenytoin | 2011 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase | 2012 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
[A woman with palmar and plantar hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Middle Aged | 2011 |
Reporting of adjuvant breast cancer trials: when is the right time?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
[A case of local-recurring breast cancer under long term-treatment by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Time Factors; Tomography, X-Ray Computed | 2011 |
[A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Health Services Needs and Demand; Hospitals, Teaching; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Satisfaction; Surveys and Questionnaires; United Kingdom | 2012 |
Multilevel latent variable models for global health-related quality of life assessment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Models, Psychological; Models, Statistical; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2012 |
[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Paclitaxel; Tomography, X-Ray Computed | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leukopenia; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Disease-Free Survival; Erythrocyte Volume; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Thymidylate Synthase; Treatment Outcome; Young Adult | 2012 |
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Tubulin Modulators | 2011 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Menstrual Cycle; Methotrexate; Middle Aged; Multivariate Analysis; Premenopause; Prognosis; Proportional Hazards Models; Retrospective Studies; Taxoids; Young Adult | 2012 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gene Expression; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Taxoids; Thymidine Phosphorylase; Tubulin | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
[Late-onset leukoencephalopathy induced by long-term chemotherapy with capecitabine and cyclophosphamide for liver metastasis from breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Leukoencephalopathies; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged | 2012 |
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Diseases; Male; Middle Aged | 2012 |
Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Middle Aged; Prodrugs; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA; DNA-Binding Proteins; Drug Eruptions; Female; Fluorouracil; Gastrointestinal Neoplasms; Gene Frequency; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Minisatellite Repeats; Mucositis; Osteosarcoma; Polymorphism, Genetic; Thymidylate Synthase; Turkey; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein; Young Adult | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
[Breast cancer and the hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paris; Prospective Studies; Risk Factors | 2012 |
[A case of metastatic pancreatic cancer which trastuzumab+capecitabine combination therapy was effective].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Trastuzumab | 2012 |
Subacute cutaneous lupus erythematosus after treatment with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous | 2013 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Models, Statistical; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2012 |
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Patient Compliance; Retrospective Studies; Severity of Illness Index; Taxoids; Vinblastine; Vinorelbine | 2012 |
[A case of cutaneous mammary re-irradiation].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lymphatic Irradiation; Mastectomy, Segmental; Neoplasm Recurrence, Local; Skin Neoplasms | 2012 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chloride-Bicarbonate Antiporters; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Membrane Proteins; Neoadjuvant Therapy; Nerve Tissue Proteins; Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; RNA, Messenger; Sulfate Transporters; Taxoids; Transcortin; Treatment Outcome | 2013 |
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prevalence; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Turkey | 2012 |
Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Odds Ratio; Receptor, ErbB-2; Taxoids | 2012 |
A rare case of non-immune hemolytic anemia in a patient with metastatic breast cancer treated with capecitabine.
Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Salvage Therapy | 2013 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional | 2013 |
[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Outpatients; Quality of Life | 2012 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
[Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Steroid | 2012 |
[Oral chemotherapy for advanced breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Molecular Targeted Therapy; Oxonic Acid; Tegafur | 2012 |
Bevacizumab in breast cancer: fundamental questions remain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel | 2013 |
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kidney Diseases; Kidney Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk Assessment; Treatment Outcome | 2002 |
Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Prodrugs | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Program Evaluation; Treatment Outcome; United Kingdom | 2002 |
Fluorouracil for allergic reactions to capecitabine.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Hypersensitivity; Female; Fluorouracil; Humans; Salvage Therapy | 2002 |
Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs | 2002 |
Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrophoresis, Capillary; Extracellular Space; Floxuridine; Fluorouracil; Humans; Prodrugs; Skin Neoplasms; Tissue Distribution | 2002 |
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrophoresis, Capillary; Fluorouracil; Humans; Microdialysis; Middle Aged | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Interactions; Epilepsy, Generalized; Female; Fluorouracil; Humans; Male; Middle Aged; Phenytoin | 2003 |
Capecitabine-induced pancreatitis.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Pancreatitis | 2003 |
Lethal toxicity of capecitabine due to abusive folic acid prescription?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Folic Acid; Humans; Middle Aged | 2003 |
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Humans; Hyperpigmentation; Nail Diseases | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2003 |
[Tumor specific therapy. Targeted breast cancer therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Prodrugs; Survival Rate | 2003 |
Complete response of brain metastases originating in breast cancer to capecitabine therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Radiography; Treatment Outcome | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Ductal, Breast; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Prodrugs | 2003 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperbilirubinemia; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prodrugs; Retreatment; Salvage Therapy | 2003 |
Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Orbital Neoplasms; Treatment Outcome | 2004 |
Tumor lysis syndrome following a single dose of capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Tumor Lysis Syndrome | 2004 |
Toxic encephalopathy induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Epilepsy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity Syndromes; Skin Neoplasms | 2004 |
Liver insufficiency due to breast cancer metastases--fast biological response with capecitabine.
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Liver Failure; Liver Neoplasms | 2004 |
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythrocyte Indices; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local | 2004 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Localization of thymidine phosphorylase in breast cancer tissue.
Topics: 5'-Nucleotidase; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Microscopy, Immunoelectron | 2005 |
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Meningeal Neoplasms; Middle Aged | 2006 |
Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; Warfarin | 2005 |
[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Floxuridine; Fluorouracil; Humans; Middle Aged; Taxoids | 2005 |
[A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |
What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival; Taxoids; Vinblastine; Vinorelbine | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Erythema; Fatal Outcome; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Paresthesia; Taxoids; Vitamin E | 2006 |
[Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; France; Hospital Costs; Humans; Middle Aged; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Pancreatic Neoplasms; Withholding Treatment | 2005 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Treatment Outcome | 2006 |
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.
Topics: Anthracyclines; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Dendritic Cells; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorouracil; Genes, Reporter; Green Fluorescent Proteins; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Interferon-gamma; Leukocytes, Mononuclear; Microscopy, Fluorescence; Neoplasm Metastasis; Remission Induction; RNA, Messenger; Taxoids; Time Factors; Transcription, Genetic; Treatment Outcome | 2005 |
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Prodrugs | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung; Lymphatic Metastasis; Lymphatic System; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Capecitabine-induced severe hypertriglyceridemia: report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Triglycerides | 2006 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
Choroidal metastasis from breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Choroid Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2006 |
Drug interaction between capecitabine and warfarin: a case report and review of the literature.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Hemorrhage; Humans; International Normalized Ratio; Neoplasm Recurrence, Local; Plasma; Warfarin | 2006 |
Acute coronary syndrome induced by oral capecitabine.
Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Liver Neoplasms; Syndrome | 2006 |
Actinic keratosis and capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Keratosis | 2005 |
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Methotrexate; Receptor, ErbB-2; Trastuzumab | 2006 |
Coronary artery spasm induced by capecitabine.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2006 |
[Patient with haemolytic anemia and treatment with capecitabine. Review of one case and literature].
Topics: Adult; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gilbert Disease; Humans; Hyperbilirubinemia; Mastectomy, Segmental; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2006 |
Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Meningeal Neoplasms; Middle Aged; Treatment Outcome | 2006 |
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2006 |
Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorouracil; Humans; Lichenoid Eruptions; Photosensitivity Disorders | 2007 |
Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with leptomeningeal metastases from breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Meningeal Neoplasms; Methotrexate; Palliative Care | 2007 |
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Models, Biological; Molecular Sequence Data; Pilot Projects; Polymorphism, Genetic; Thymidylate Synthase | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Skin Neoplasms | 2006 |
[Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Mastectomy; Quality of Life; Trastuzumab | 2006 |
[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Fluorouracil; Hand Dermatoses; Humans; Necrosis; Skin; Skin Ulcer; Time Factors; World Health Organization | 2007 |
[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Topics: Adult; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astringents; Breast Neoplasms; Capecitabine; Deoxycytidine; Exudates and Transudates; Female; Fluorouracil; Hallux; Humans; Keratosis; Mupirocin; Nail Diseases; Ointments; Paclitaxel; Time Factors; Treatment Outcome; Zinc Sulfate | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Targeted therapy for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
[Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Mastectomy; Radiography, Abdominal; Tomography, X-Ray Computed | 2006 |
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Neoplasm Recurrence, Local; Quality of Life; Toremifene | 2007 |
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome; Viscera | 2007 |
Lapatinib plus capecitabine in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy, Radical; Middle Aged; Nitriles; Parotid Gland; Parotid Neoplasms; Receptors, Estrogen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Elementary, my dear Watson.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Dose-Response Relationship, Drug; Emigration and Immigration; Female; Fluorouracil; Foot; Hand; Humans; Neoplasm Metastasis | 2007 |
Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2007 |
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Thymidine Phosphorylase | 2007 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Electrocardiography; Female; Fluorouracil; Head and Neck Neoplasms; Heart; Heart Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Prospective Studies | 2008 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Paresthesia; Postoperative Period; Syndrome | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Skin Neoplasms; Tegafur; Toremifene | 2007 |
[Capecitabine-induced hyperpigmentation].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigmentation; Mastectomy, Radical; Middle Aged; Paresthesia | 2007 |
Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Recurrence, Local; Radiography; Trastuzumab | 2007 |
Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans | 2007 |
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Failure | 2008 |
Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclooxygenase 2; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Kinetics; Luminescence; Tetrazolium Salts; Vinblastine; Vinorelbine | 2007 |
Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Flow Cytometry; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Luminescence; Taxoids; Tetrazolium Salts | 2007 |
[A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Treatment Outcome | 2007 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Treatment Outcome | 2007 |
FDA approves new breast cancer treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Contraindications; Deoxycytidine; Drug Approval; Drug Labeling; Epothilones; Fluorouracil; Humans; Tubulin Modulators; United States; United States Food and Drug Administration | 2007 |
Granulomatous septal panniculitis associated with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Biopsy; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Panniculitis; Skin | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Taxoids | 2007 |
Capecitabine-related cardiotoxicity: recognition and management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Heart Diseases; Humans; Incidence; Male; Middle Aged; Prodrugs; Rectal Neoplasms | 2008 |
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Taxoids; Trastuzumab | 2008 |
[Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Neoplasm Staging; Recurrence; Tomography, X-Ray Computed; Trastuzumab | 2008 |
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Polymorphism, Genetic | 2008 |
Capecitabine induced inflammation of actinic keratoses.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Keratosis; Ultraviolet Rays | 2007 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Forecasting; Humans; Immunohistochemistry; Middle Aged; Retrospective Studies; Therapeutic Equivalency; Thymidine Phosphorylase; Treatment Outcome | 2008 |
[A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Recurrence; Taxoids; Time Factors; Tomography, X-Ray Computed | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Staging; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cerebellar Ataxia; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines | 2008 |
Ten years of HER2-directed therapy: still questions after all these years.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Forecasting; Humans; Lapatinib; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2009 |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA, Neoplasm; Female; Fluorouracil; Genotype; Humans; Multivariate Analysis; Pilot Projects; Polymorphism, Genetic; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Meningeal Neoplasms; Trastuzumab | 2009 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Trastuzumab and capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Costs and Cost Analysis; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Trastuzumab | 1998 |
Positive results achieved with new oral chemotherapy agent.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oncology Nursing | 1999 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1999 |
Radiology's role widens in therapeutic drug development and trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Drug Therapy; Female; Fluorouracil; Humans; Male; Radiology; United States; United States Food and Drug Administration | 1999 |
Severe ocular irritation and corneal deposits associated with capecitabine use.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Corneal Diseases; Deoxycytidine; Female; Fluorouracil; Humans; Keratitis; Keratoconjunctivitis Sicca; Middle Aged; Visual Acuity | 2000 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Coronary spasm induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chest Pain; Coronary Angiography; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged | 2001 |
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Prodrugs | 2001 |
Onychomadesis and onycholysis associated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Nails, Malformed; Prodrugs | 2001 |
[Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Taxoids; Treatment Failure; Treatment Outcome | 2001 |
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Intestinal Mucosa; Middle Aged; Mouth Mucosa; Perineum; Stomatitis | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Clinical picture: leopard-like vitiligo with capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Vitiligo | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Fluorouracil; Humans; Immunoenzyme Techniques; Membrane Transport Proteins; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Thioinosine | 2002 |
Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
An evolving role for oral fluoropyrimidine drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Therapy; Enzyme Inhibitors; Female; Fluorouracil; Humans; Pyrimidines; Uracil | 2002 |
Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Transplantation, Heterologous; Trastuzumab; Tumor Cells, Cultured | 2002 |
Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Hip; Humans; Middle Aged; Radiodermatitis; Radiotherapy | 2002 |